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Heart failure
Heart failure is a complex clinical syndrome that can result from any structural
or functional cardiac disorder that impairs the ability of the ventricle to fill with
or eject blood (1). Coronary artery disease is the underlying cause of heart
failure in approximately two thirds of patients with left ventricular systolic
dysfunction (2). Other important causes of heart failure include hypertension,
valvular disorders and cardiomyopathies (3). Defining heart failure is not simple,
and many definitions have been used throughout the years. A pragmatic
definition of heart failure would be: a clinical syndrome caused by an
abnormality of the heart and identified by a characteristic pattern of
hemodynamic, renal, neural and hormonal responses (4). After the initial
cardiac injury, patients may remain asymptomatic for a long time (Fig.1).
Figure 1. Heart failure is a progressive, lethal syndrome characterized by accelerating
deterioration, following a period of asymptomatic left ventricular dysfunction.
(Reproduced with permission from AM Katz. Heart Failure. Pathophysiology, molecular
biology, and clinical management. Lippincott Williams and Wilkins, Philadelphia,
2000)
The cardinal manifestations of heart failure are dyspnea and fatigue, which
may limit exercise tolerance, and fluid retention, which may lead to pulmonary
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and peripheral edema (1). There is no simple pathophysiologic explanation for
the genesis of these symptoms. Complaints of dyspnea are not related to the
level of pulmonary artery pressure (5), and the limiting symptom during
progressive exercise testing can be altered from fatigue with slow exercise
protocols to dyspnea with faster exercise protocols (6). Furthermore, in heart
failure there is no good correlation between the severity of cardiac dysfunction
and the degree of functional impairment (7,8). It is now thought that
abnormalities in peripheral blood flow and in skeletal muscle are important for
the origin of symptoms and may also play a role in the progression of the
syndrome (9).
The scope of the problem of heart failure
Heart failure is one of the fastest growing problems in cardiovascular medicine.
This increase can be contributed to aging of the population and improved
survival after myocardial infarction, as well as better treatment of heart failure
patients (10), since treatment does not cure the disease but improves survival of
the patients. The incidence of heart failure in the general population rises very
steeply with age, from 0.02 cases per 1000 population per year in those aged
25-34 years, to 11.6 in those aged 85 years and over (11,12). A higher
incidence of heart failure was found in the Framingham cohort, increasing
steeply to an incidence of 27 cases per 1000 population per year in men 80 to
89 years old (13). The incidence of heart failure is about twice as high in males
than in females (11). Coronary artery disease and hypertension are the most
frequent causes of heart failure (11). It is estimated that the prevalence of heart
failure and left ventricular dysfunction in a Western European population is
about 1 % of the population (14). Heart failure is now the most common
discharge diagnosis in patients older than 65 years. Recently a new approach to
the classification of heart failure has been suggested by the American College
of Cardiology and the American Heart Association, that emphasizes both the
evolution and the progression of the disease and can be used to complement
the New York Heart Association functional classification(1). In this classification
four stages of heart failure are identified: Stage A identifies the patient who is at
high risk for developing heart failure but has no structural disorder of the heart;
Stage B refers to a patient with a structural disorder of the heart but who has
never developed symptoms of heart failure; Stage C denotes the patient with
past or current symptoms of heart failure associated with underlying structural
heart disease; and  Stage D designates the patient with end-stage disease who
requires specialized treatment strategies such as mechanical circulatory
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support, continuous inotropic infusion, or heart transplantation (1). In the
evaluation of patients with heart failure a complete echocardiographic
examination is the single most useful diagnostic test (1) but will not be
discussed in this text. The prognosis of heart failure is grim and as poor as many
malignancies. In the general population the mortality of patients with heart
failure is twice that of persons without heart failure showing an 1, 2 and 5
years’ survival of 89%, 79% and 59%, respectively with a fivefold increase in
sudden death rate (15). In patients with NYHA class III or IV symptoms, the
one-year mortality was 35% and the combined rate of mortality and/or
readmission in hospital 81 % (16). Patients with end-stage heart failure have an
even poorer prognosis: 75 % mortality after one-year (17). Mortality is either
sudden or due to progressive pump failure. Sudden death, mostly caused by
ventricular fibrillation or ventricular tachycardia, accounts for nearly half of the
cardiovascular deaths (18). Progressive pump failure accounts for the other 30-
50% and becomes even more important in end-stage heart failure. A small
number of patients die due to electromechanical dissociation or bradycardia.
Treatment
The management of patients with heart failure has changed considerably during
the last decades. Current therapy has two important goals: improvement of
symptoms and improvement of prognosis. A challenge for the near future will
be the prevention of left ventricular dysfunction by aggressively treating
ischemic heart disease, and preventing the transition of asymptomatic cardiac
dysfunction to symptomatic heart failure.
Treatment of every heart failure patient has to be individualized and begins
with defining the cause of the syndrome. In some patients this directly indicates
the optimal therapy, as for instance in the case of patients with primary valvular
pathology. In ischemic heart disease, the diagnosis of hibernating myocardium
can also influence the therapy substantially. Other potentially reversible causes,
like hyperthyroidism, anemia, or alcohol abuse, have to be looked for.
General measures are often overlooked, but may influence the therapeutic
response considerably. Weight reduction in the obese, sodium and fluid
restriction, reduction of alcohol intake and cessation of smoking have to be
stressed. The patient has to be educated about the importance of adequate drug
dosing and the early detection of fluid retention by regular weighing. Drugs like
NSAID’s should be avoided because of their potential adverse effects like fluid
retention and renal failure. Regular exercise in stable patients should be
encouraged, because this can improve exercise capacity, even in patients with
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severe heart failure (19).
Pharmacological therapy in heart failure comprises an increasing number of
drugs but will not be discussed here, because it is outside the scope of this
thesis. In the treatment of patients with end-stage heart failure the
pharmacological options are limited and therefore, heart transplantation is often
considered.
Heart transplantation
The first human heart transplantation was performed in 1967. It was followed
by a period of hectic activity in heart transplantation worldwide. The initial
results, however, were very disappointing, resulting in the discontinuation of
heart transplantations in most centers. The majority of patients died because of
acute rejection or infection. The development of a biopsy forceps by Philip
Caves in Stanford enabled the monitoring of acute rejection, further supported
by a histologic grading system introduced by Billingham (20). In 1980
cyclosporin was introduced as immunosuppressive treatment after
transplantation. This resulted in a considerable improvement in 1-year survival
in comparison with the “classic” immunosuppression with corticosteroids and
azathioprine. From that time a dramatic expansion of heart transplantation
occurred. To date, more than 57.000 heart transplants have been performed
worldwide (21). However, from 1996 the annual number of transplants is
declining, and now approaches 3000, despite the fact that all transplant centers
accept increasingly older donors, with a maximum age of 55-60 years old. Age
distribution of patients receiving heart transplants clusters between the ages of
40-60 years. One-year survival is 80-85 % with a further constant mortality rate
of 4% per year. The patient half-life (time to 50% survival) is 9.1 years, and in
those surviving the first year, the patient half-life is 11.6 years (21). Functional
improvement is impressive, enabling patients to live a near normal life and
often to resume work. Due to the shortage of donor hearts, heart transplantation
can only be offered to a highly selected group of patients. It requires lifelong
immunosuppressive medication and close follow-up. Major problems comprise
acute rejections, infections, cardiac allograft vasculopathy, hypertension, renal
failure and malignancies.
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Figure 2. The number of heart transplantations performed per year in the University
Medical Center Utrecht
In the Netherlands two centers are performing heart transplantations, Rotterdam
and Utrecht. Due to the lack of donor-organs, both centers together transplant
only about 40 patients each year, despite the acceptation of more and more
marginal and older donors.
 In the University Medical Center Utrecht, from the beginning of heart
transplantation in 1985, 300 transplants have been performed. Figure 2 shows
the yearly number of transplants. Actuarial survival is shown in figure 3,
demonstrating a 5-year survival of 75 % and a 10-year survival of 64 %.
The recently introduced law on organ donation has not resulted in an increase
of donor-organs, but in contrast, seems only to has made things worse. The
number of available donor organs is also influenced by the increased traffic
safety precautions and by the improved treatment options to prevent brain
death.
It is not to be expected that the number of available donor-hearts will increase
substantially during the coming years. Therefore, it is necessary to explore
other therapeutic options for patients with end-stage heart failure, such as
mechanical circulatory support.
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Figure 3. Actuarial survival after heart transplantation in the UMC Utrecht
Mechanical circulatory support
Mechanical circulatory support was first used in 1954 with the implementation
of the cardiopulmonary bypass by Gibbon. This not only led to the
breakthrough of cardiac surgery, but also stimulated research into techniques
for supporting the circulation in severe heart failure. In 1969, only two years
after the first human heart transplantation, a pneumatic total artificial heart was
used for the first time as a bridge to transplantation (22). Subsequently, a variety
of extracorporeal and implantable assist devices was developed. These devices
can be arbitrarily divided in devices meant for short-term support (up to ± 2
weeks), or long-term support. Short-term devices include the intra-aortic
balloon pump (IABP) and external centrifugal and pneumatic devices, like the
Abiomed BVS 5000.
The IABP was first used in 1967 and since that time in millions of patients. Its
main indications are postcardiotomy low cardiac output and pump failure after
acute myocardial infarction. The increased waiting period for donor hearts
limits its use as a bridge to transplantation. The IABP results in a modest
increase in cardiac output up to 20%. The main shortcoming of the IABP is that
it does not produce flow on its own; it merely augments heart function
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modestly.
On the other hand, external centrifugal and pneumatic devices can support the
circulation even in the absence of native heart function. The duration of
support with these devices, however, is limited due to bleeding,
thromboembolism, infection and renal dysfunction (23). The main indication is
hemodynamic support in postcardiotomy shock.
Some examples of long-term assist devices are the Thoratec (Thoratec,
Pleasanton, Calif), the Novacor (WorldHeart, Ottawa) and the HeartMate
(Thoratec, Pleasanton, Calif).
The Thoratec ventricular assist device can be used for univentricular, as well as
for biventricular support. It is a paracorporeal, pneumatically powered system,
using a large driving console, although a portable driver recently has become
available. The pumps are placed externally on the anterior surface of the
abdomen, limiting mobilization of the patient. Furthermore, intensive
anticoagulation is required (24).
The Novacor is an electrically driven, implantable pump, limited to left
ventricular support. It has a smooth blood-contacting surface that requires
anticoagulation and nevertheless has a higher thromboembolic rate than the
other devices (25).
The HeartMate is also an implantable pump, which supports only the left
ventricle (Fig. 4). Two models are available; a pneumatically driven version (IP),
with an external driving console and an electrically driven version (VE). The
pump consists of a titanium housing with a flexible Biomer polyurethane
diaphragm bonded to a rigid pusher plate. The diaphragm divides the pump into
two halves: a blood chamber and an air chamber in case of the IP system or an
electrical motor chamber in case of the VE system. The air chamber of the IP
system is connected to an external console by a transcutaneous driveline (Fig. 5).
In contrast to the Novacor its textured polyurethane and sintered titanium lining
makes anticoagulation unnecessary, except for low-dose aspirin. It has a low
thromboembolic rate (3-6%), but a higher rate of reported device-related
problems compared to the other devices (25-27). In the REMATCH Study
Group the probability of device failure was 35% at 24 months (17). The device
is implanted in an intra-abdominal position. The device is connected by
cannulas, containing porcine valves, between the apex of the left ventricle and
the base of the aorta (23) (Fig. 6). Maximum stroke volume of the blood
chamber is 83 ml. The flow range is approximately 2-10 liters/min. It can be
operated in a “fixed rate mode” and an “auto rate mode”. In the auto mode the
HeartMate functions in a ‘fill-to-empty’ manner which permits the device to
vary its flow based on the patient’s physiological need, dependent on left
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ventricular filling.
Figure 4. The HeartMate VE left ventricular assist device.
The HeartMate is presently only approved for the use as a bridge to heart
transplantation. More than 2700 patients around the world have been treated
with this device (26), representing an overall experience of over 500 patient-
years of support. Survival to transplantation in several reports varied from 65 to
76% (26-28). Furthermore, outcome after heart transplantation in patients
supported with an internal LVAD is as good as that of patients transplanted after
support on inotropic medical therapy (29). Obviously the use of LVAD’s as a
bridge to transplantation does not result in more heart transplantations; but the
LVAD can help the sickest patient, who would die on medical therapy, survive
to transplantation. Recently the suitability of the HeartMate LVAD as a long-
term myocardial-replacement therapy was evaluated in patients ineligible for
heart transplantation (REMATCH) (17). This study showed a survival rate at one
year of 52% in the device group and 25% in the medical therapy group
(p=0.002). The rates at two years were 23 % and 8 % (p=0.09), respectively.
These findings establish the LVAD, not only as a bridge, but also as an
alternative to heart transplantation in selected patients with end-stage heart
failure (17), although longevity with the current device is limited by a high
incidence of infections and device malfunctions.
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Figure 5.  Cross section of the HeartMate IP LVAD showing a blood chamber and an air
chamber divided by a pusher plate. Pulses of air, delivered by the pneumatic console,
result in displacement of the pusher plate, propelling the blood out of the pump. Two
porcine xenograft valves provide unidirectional flow.
Figure 6. Schematic diagram of the HeartMate VE left ventricular assist device. The
inflow canula is implanted in the left ventricular apex. The outflow graft is connected
end to side to the ascending aorta.
General introduction
19
Besides the use of LVAD’s as a bridge to transplantation or as an alternative to
heart transplantation it is suggested that they can be used as a bridge to
recovery of cardiac function (30,31). Prolonged mechanical circulatory support
effectively unloads the left ventricle, resulting in a decrease of cardiac
dimensions (32-34) and cardiomyocyte size (35,36), improvement of myocyte
contractile function (37,38) and decrease of neurohormonal activation (39,40).
Few centers have limited experience with weaning patients from the device
(41-43), whereas others question the feasibility of this policy (44,45). At this
moment it is not yet clear if reversed remodeling of the left ventricle after
mechanical support will be sufficient to allow for device removal; also, it
remains to be seen how long this effect will last.
Newer developments in mechanical support.
Several newer devices will become available within a couple of years. These
devices will offer greater durability and longevity, enabling their use as a
realistic alternative to transplantation. Some examples are the HeartMate II (Fig
7) and the Jarvik 2000 (30), high-speed rotary axial flow pumps, which are fully
implantable and much smaller than the present HeartMate. In the future, they
will be powered by a transcutaneous energy transfer system.
Figure 7. The HeartMate II axial flow pump
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The HeartMate III is a centrifugal pump of which the rotor is magnetically
suspended, which will extend the lifespan of this system greatly. A completely
new total artificial heart (Abiocor) will also be available in the near future. In
contrast to the previous devices, the Abiocor will replace the native heart.
Indications and contra-indications for these newer devices will be an area of
research for the coming years.
LVAD’s as a means to study fundamental aspects of end-stage heart failure.
Implantation of a LVAD requires the removal of a part of the apex of the left
ventricle to allow for insertion of the inflow canula. Therefore, the use of a
LVAD as a bridge to transplantation offers the unique opportunity to obtain
human myocardial tissue from patients with end-stage heart failure at a time
when they are in a critical hemodynamic condition. Later in the course of
therapy, when the patient has recovered thanks to the LVAD support, heart
transplantation offers a second opportunity to obtain human myocardial tissue.
In this way, human myocardial tissue of patients with end-stage heart failure, at
two points in time, can be compared. This allows the study of more
fundamental aspects of end-stage heart failure, like the evaluation of the
morphology of the contractile filaments, and the role of apoptosis and its
regulating mechanisms in end-stage heart failure.
The ultrastructure of the heart
The heart is composed of a syncytium of longitudinally arranged myocytes,
interspersed with connective tissue elements and blood vessels (46). Each
myocyte is surrounded by a cell membrane, the sarcolemma, and is filled with
rodlike bundles of myofibrils and many mitochondria (47) (Fig. 8). These
myofibrils are the contractile elements, consisting of serially connected
contractile units known as sarcomeres. The sarcomere is composed of
contractile, regulatory, and structural proteins arranged into thick and thin
filaments (Fig.9) (46). The sarcomere is limited on either side by the Z line. In
the Z lines the thin contractile filaments are anchored, consisting mainly of two
strands of actin intertwined with tropomyosin. At regular intervals along this
structure the troponin complexes are situated (Fig. 10). Troponin T binds the
troponin complex to tropomyosin; troponin C is a calcium binding protein,
necessary for the excitation-contraction coupling, and troponin I inhibits the
interaction between actin and myosin (3). The thick contractile filaments
mainly consist of myosin, which are anchored at the M line, in the middle of
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the sarcomere. Titin is a large elastic molecule that supports myosin and binds
it to the Z line (47). Sarcomere shortening in the contracting heart occurs when
the thin filaments are pulled toward the center of the A-band by a rowing
motion of the myosin cross-bridges (3). The energy required for these
contractions is derived from ATP hydrolysis by myosin.
Figure 8. Ultrastructure of the cardiomocyte. Each sarcomere is bounded by two Z-lines
in which the thin contractile filaments are anchored. The thin contractile filaments on
either side of the Z-line represent the I-band. The A-band represents the region of the
sarcomere occupied by the thick filaments into which the thin filaments extend from
either side. (Reproduced with permission from AM Katz. Heart Failure.
Pathophysiology, molecular biology, and clinical management. Lippincott Williams
and Wilkins, Philadelphia, 2000)
Two isoforms of myosin heavy chain (MHC) are known in the heart: α-MHC
and β-MHC. α-MHC contains high ATPase activity, which results in fast muscle
contraction and high myocardial contractility. Human atrium contains mainly
the α-MHC isoform. On the other hand β-MHC has low ATPase activity,
resulting in a slower, weaker, but more efficient contraction. Human ventricular
myocytes contain 90 % β-MHC isoform (3). Heart failure is associated with a
shift in MHC isoform from the fast (α-MHC) to the slow type (β-MHC),
especially in atrial myocytes, but also in ventricular myocytes (48). This re-
expression of immature fetal cardiac genes like fetal contractile proteins and
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natriuretic peptides is a feature of cardiac hypertrophy (49). It can be adaptive
and promote a more favorable myoenergetic economy, but the functional
implications of many of these changes are still unclear (50). Mutations in many
cardiac proteins can be responsible for familial cardiomyopathies. Mutations in
myofibrillar proteins are thought to result mainly in hypertrophic
cardiomyopathy whereas mutations in cytoskeletal proteins mostly result in
dilated cardiomyopathy (49). This dichotomy probably is a too simple
pathophysiologic model, because mutations in β-myosin heavy chain and
troponin T have recently been associated with dilated cardiomyopathy as well
(51,52). Therefore, divergent signaling pathways have to be present,
remodeling the heart in ways that result in either a dilated or a hypertrophic
phenotype. Maybe in the future, these pathways may be used to direct
therapeutic interventions to prevent or to abrogate disease progression in
cardiomyopathy.
Figure 9. The sarcomere is limited on either side by a Z-line, in which the thin
contractile proteins (actin/tropomyosin complex) are anchored. The myosin filaments
are anchored in the M-line, in the middle of the sarcomere. The myosin heads, attached
to the thick filaments, interact with the thin filaments. As a result the actin filaments
move inward towards the center of the sarcomere, drawing the Z-lines closer together.
Mechanisms of heart failure
Heart failure may be viewed as a progressive disorder that is initiated after an
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index event resulting in either loss of cardiomyocytes or deterioration of
myocyte function, producing a decline in pumping capacity of the heart.
Regardless of the nature of the initial event, a variety of compensatory
mechanisms become activated (53). These compensatory mechanisms include
the adrenergic nervous system (54), the renin-angiotensin system (55) and
cytokine systems (56, 57).
Figure 10. The thin contractile filament consisting of two strands of actin intertwined
with tropomyosin. At regular intervals the troponin complexes are situated, consisting
of troponin T, C and I.
This neurohormonal activation in heart failure is similar to the response to
hypovolemia, hemorrhage, and exercise. It is an old evolutionary mechanism
aimed at maintaining blood pressure, perfusing the brain, and exercising
muscles so as to sustain physical activity (4). In the short-term these systems
modulate cardiovascular function, so that the functional capacity of the patient
is initially preserved. Why and when the transition to symptomatic heart failure
occurs is unknown, but it is accompanied by further activation of
neurohormonal and cytokine systems as well as adaptive changes within the
myocardium, collectively referred to as remodeling (53).
Remodeling
Cardiac remodeling may be defined as genome expression, molecular, cellular
and interstitial changes that are manifested clinically as changes in size, shape
and function of the heart after cardiac injury (58). The central feature of
myocardial remodeling occurring secondary to hemodynamic overload is an
increase in myocardial mass associated with a change in the shape of the
ventricles (59). Pressure overload results in increased myosin heavy chain
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synthesis in the heart in vivo, within hours (50). The increase in systolic wall
stress results in parallel addition of sarcomeres, increasing the width of
individual cardiomyocytes and therefore causing concentric hypertrophy at the
gross morphologic level. On the other hand, pure volume overload results in
the addition of sarcomeres in series and lengthening of cardiomyocytes,
causing eccentric hypertrophy at the gross morphological level (59). A number
of factors have been identified as potential causes of myocyte hypertrophy, as
indicated in table 1 (60). Initially, this hypertrophy is compensatory to the
increased workload of the ventricle. Later, the process becomes maladaptive
leading to ventricular failure. In this phase several events take place, like
necrosis, apoptosis, fibrosis, increased fibrillar collagen deposition, and
fibroblast proliferation. Structural changes reported in cardiomyocytes in this
phase are loss of myofilaments and alterations in cytoskeletal proteins (61). In
addition, vacuoles, myelin figures, increased amounts of lipofuscin and lipid
droplets, all morphological consequences of cellular degeneration, are reported
(62).
norepinephrine
angiotensin II
endothelin 1
fibroblast growth factor (FGF)
transforming growth factor-ß1 (TGF ß1)
tumor necrosis factor-α (TNFα)
interleukin-1β (IL-1β)
G protein 130-signaling cytokines
Table 1. Mediators of hypertrophy in heart failure
Evidence that neurohormonal activation itself can contribute to the progression
of heart failure is for example based on a study in rats, showing that angiotensin
II infusion was associated with altered sarcolemmal permeability and
myocytolysis, with subsequent fibroblast proliferation and scar formation (63).
This effect could be successfully blocked by captopril. Angiotensin II is also
thought to release TGF-ß, which is contributory to phenotypic transformation of
recruited interstitial fibroblasts into myofibroblasts (64). These myofibroblasts
are responsible for an increased production of collagen I and III and also
demonstrate contractile behavior, which governs matrix remodeling, including
scar thinning (64).
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Another finding supporting the potential adverse effects of neurohormonal
activation is that adrenergic stimulation in isolated cardiomyocytes resulted in
cyclic AMP-mediated calcium overload with a resultant decrease in RNA and
protein synthesis, as well as decreased cell viability (65).
Ongoing myocyte cell death is thought to be an important mechanism leading
to progressive ventricular dysfunction (66). The importance of myocyte cell
death in the genesis of heart failure can simply be deduced from experience
after myocardial infarction. The extent of the necrotic area determines the
hemodynamic consequences and prognosis. Cardiogenic shock shortly after
acute myocardial infarction will only be seen when approximately 50 % of the
left ventricular myocardium is necrotic, whereas patients with smaller
infarctions will rarely develop cardiogenic shock (67). Animal studies also stress
the importance of progressive cell death in heart failure. For example,
inhibition of myocyte cell death by insulin-like growth factor-1 in models of
ischemic cardiomyopathy resulted in attenuation of ventricular dilatation,
reactive hypertrophy, and diastolic wall stress (68,69). In this particular study
necrosis was the predominant form of myocyte cell death, but it underscores a
role for cardiomyocyte cell death, either by necrosis or by apoptosis, in the
origin of heart failure.
Fundamental in the hypothesis of the role of cadiomyocyte cell death in heart
failure is the concept that adult cardiomyocytes are terminally differentiated
and have no capacity for self-renewal. Recent literature, however, has
challenged this dogma (70-72). This potential for myocyte proliferation might
counteract some myocyte cell death, although we do not yet know how
extensive this effect will be (73). Therefore, myocyte cell death is still thought
to be an important factor in the pathogenesis of heart failure. Necrosis is the
main form of cell death in myocardial infarction. Apart from necrosis, however,
apoptosis may play a role in cardiomyocyte cell death although it is not yet
known to what extent (74,75).
Apoptosis
There is no field of basic cell biology and cell pathology that is more confusing
and more unintelligible than is the area of apoptosis versus necrosis (76). Cell
death is a process that contains a point of no return long before any necrotic
changes can be seen by light microscopy (77). Therefore, some reports
recommend that the term necrosis should be reserved for those changes that
occur after cell death regardless of the pathway by which the cells died (78).
These necrotic changes include karyolysis, pyknosis, karyorhexis, condensation
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and intense eosinophilia of the cytoplasm, loss of structure and fragmentation
(77). In this view the two major forms of cell death are apoptosis and oncosis
(Fig.11). Oncosis is cell death characterized by cellular swelling, organelle
swelling, blebbing and increased membrane permeability. It is often caused by
ischemia and toxic agents and leads to DNA breaks in a nonspecific fashion
(77). Cell removal is by inflammation (79), eventually leading to fibrotic
scarring.
Apoptosis, or programmed cell death, is an evolutionary conserved genetically
programmed process by which multicellular organisms regulate their cell
numbers. It is critical in embryonic development, eliminating unneeded cells
and in tissue homeostasis, eliminating for example damaged, premalignant cells
and immune-effector cells (80). First reported by Kerr et al. (81) in 1972, this
energy dependent form of cell death does not evoke a fibrotic reaction, in
contrast to oncotic cell death.
Apoptosis is characterized by cell shrinkage, nuclear chromatin condensation
(pyknosis), preservation of mitochondrial and sarcolemmal integrity and the
emission of cell organelles by pseudopodia called budding (77, 79). DNA is
broken down into segments that are multiples of approximately 185 base-pairs,
due to specific cleavage between nucleosomes. Apoptosis hardly induces an
inflammatory response and cell removal is done by macrophages or
neighboring cells. Apoptosis can be initiated by an internal clock, or by
extracellular agents such as hormones, cytokines, killer cells, and a variety of
chemical, physical and viral agents (77).
The suggested model of apoptotic cell death and oncotic cell death, both
resulting in necrosis (77) is basically attractive but has not received much
support in literature. Most reports oppose apoptosis to necrosis. For
simplification, the latter model will be used further. Apoptosis and necrosis
may share common mechanisms in the early stages of cell death (82) and
intermediate types of cell death, called aponecrosis  have been seen (83) as
well as secondary necrosis in initially apoptotic cells (82). The activation of
caspases and the presence of ATP are crucial for the determination between
apoptotic and necrotic cell death (84).
The detection of apoptosis is based on different molecular methods including
the typical ladder pattern of DNA in agarose gel electrophoresis, as a result of
the DNA fragments that are multiples of 180-200 base-pairs. This is a very
sensitive technique, but does not reveal which cell type is apoptotic in the
tissue (79).
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Figure 11. The two types of cell death. On the left side oncosis characterized by
cellular swelling, organelle swelling, blebbing and increased membrane permeability.
On the right side apoptosis is shown characterized by cell shrinkage, nuclear chromatin
condensation (pyknosis), the preservation of mitochondrial and sarcolemmal integrity
and the emission of cell organelles by pseudopodia called budding. (Reproduced with
permission from Majno G and Joris I. Apoptosis, oncosis, and necrosis. An overview of
cell death. Am J Pathol 1995; 146: 3-15).
The most widely used technique for the detection of apoptosis is the in situ
end-labeling of fragmented DNA (TUNEL) method (85). This sensitive method
enables the in situ visualization of the apoptotic process at the single cell level,
but has several limitations (86). It is not yet known how many DNA strand
breaks will result in a positive signal, and positivity may persist after complete
DNA fragmentation has occurred. Furthermore, necrotic cardiomyocytes and
cardiomyocytes showing postmortem autolysis may also be labeled (87) as well
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as viable cardiomyocytes showing DNA repair (88) and RNA synthesis (89).
These limitations of the TUNEL method may partly explain the different
percentages of apoptotic cardiomyocytes reported in end-stage heart failure
patients. Narula et al. (90) reported an apoptotic index of 5-35%, Olivetti (91)
0.23% and Saraste (92) 0.12%. In patients with end-stage heart failure who
received a left ventricular assist device, however, apoptosis of cardiomyocytes
could not be demonstrated, but apoptosis of cardiac interstitial cells, such as
fibroblasts and endothelial cells, was not uncommon (93).
Apoptosis is a very fast process, taking 6 to 24 hours at most (85, 86).
Therefore, the initially reported levels of apoptosis of up to 35 % (90) are
unrealistically high, because this would result in the demise of all
cardiomyocytes within very short time. The widely varying values of incidence
of apoptosis, reported in the literature, point out that the role of apoptosis in
heart failure needs substantiation (86). Despite the large number of reports in
literature dealing with apoptosis and heart failure, a causal role for apoptosis in
human heart failure has not been proven, but there are many arguments that
apoptosis of cardiomyocytes is a feature of both ischemic and non-ischemic
heart failure (94). Myocardial stretch results in an increased incidence of
apoptosis (95). The same holds for exposure to angiotensin II (96,97) and
norepinephrine (98). Consistent with these findings, ACE-inhibitors (99) and
beta-blockers (100,101) attenuate cardiomyocyte apoptosis. Furthermore,
increased cytosolic calcium, oxygen free radicals and hypoxia can lead to
apoptosis (66). Ischemia itself also increases cardiomyocyte apoptosis incidence
(102-104). In acute myocardial infarction, apart from necrosis, apoptosis is
reported (105), especially in the border zone (106). In hibernating myocardium,
continuing myocyte loss by apoptosis may explain the lack of complete
functional recovery after revascularization (107-109).
Regulation of cardiac apoptosis
The regulation of apoptosis is a very complicated process in which many
factors are involved. In this overview, only the essential factors will be
discussed. A key phenomenon of apoptotic cell death is the activation of a
unique class of cysteine proteases, known as interleukin converting enzymes
(ICE), more recently referred to as caspases (110,111). They exist as pro-
enzymes that are activated by cleavage at specific protein sequences. Following
activation these enzymes have proteolytic activity and cleave specific
substrates. Caspase-3, 8 and 9 are important in cardiac myocyte apoptosis.
Caspase-3 represents the final common pathway of the caspase cascade,
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activating endonuclease, which degrades DNA (112).
Apoptosis can be schematically initiated in two ways: “death-receptor”
mediated apoptosis and “mitochondrion” dependent apoptosis (113) (Fig. 12).
Death-receptor mediated apoptosis involves the binding of extracellular death
signal cytokines, like TNFα and FasL, to their cognate cell surface receptors,
TNF-R1 and Fas, respectively (113). This binding activates death domain
proteins, which interact with caspase-8 (formerly named FLICE), further
initiating the apoptosis cascade. The interaction between death-receptors and
death domains can be inhibited by FLICE (caspase-8)-inhibitory proteins (FLIPs)
(114), which are expressed at high levels in the heart (115).
Figure 12. Schematic representation of the caspase cascade in apoptosis. On the left
side death receptors are activated by TNFα or FasL resulting in caspase-8 and caspase-3
activation. Caspase-8 (FLICE) can be inhibited by FLICE inhibitory protein (FLIP). On
the right side of the figure the mitochondrial pathway is shown, in which caspase-9
activation results in apoptosis by activating caspase-3. The balance between Bax and
Bcl-2 regulates this process. AIF= apoptosis inducing factor. Binding of TNFα to TNF-
R1 can also activate NF-κB which can stimulate production of nuclear survival proteins,
blocking apoptosis (not shown).
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Mitochondrion dependent apoptosis results from metabolic stress, like hypoxia,
ischemia and acidosis, resulting in the mitochodrial release of cytochrome-c, or
apoptosis-inducing factor (AIF), both activating caspase-9, that subsequently
activates caspase-3 (112). The release of cytochrome-c can directly be blocked
by Bcl-2, a member of a family of human apoptosis regulating proteins (116).
Bcl-2 also binds to and inactivates the pro-apoptotic family member Bax (112).
The ratio of Bcl-2 to Bax, the so-called “death switch” is often used as an
indicator of apoptosis (66).
Another regulator of apoptosis is the transcription factor NF-κB. Binding of
TNFα to TNF-R1 can result in apoptosis by activation of the death domain
pathway, but it can also trigger NF-κB activation, which leads to gene products
that block the apoptotic pathway (117). It was thought that TNFα can only
result in apoptosis if NF-κB is blocked simultaneously (118). But to complicate
things even more, it has been shown that NF-κB itself can promote apoptosis,
depending on the cell type and the nature of the apoptosis-inducing stimulus
(118). A factor also involved in the regulation of apoptosis is the tumor
suppressor protein p53, which is believed to induce apoptosis in response to
DNA damage (66) and other signals like stretch-mediated release of angiotensin
II (97).
Figure 13. Some triggers of cardiomyocyte apoptosis in heart failure.
In heart failure many stimuli are known to result in apoptosis (Fig.13). The
exact mechanisms by which these stimuli trigger apoptosis are often unknown.
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In the transition between compensated hypertrophy and overt cardiac failure
apoptosis may be a critical event. This has been suggested by a study in
spontaneously hypertensive rats. Rats showing signs of heart failure had a five-
fold increase in the number of apoptotic cardiomyocytes in comparison with
rats without heart failure (119).
Another argument in favor of the importance of apoptosis in the transition of
compensatory hypertrophy to heart failure comes from a study in transgenic
mice that harbor a knockout of the gp 130 cytokine receptor. The gp130
cytokine receptor is a common subunit of the interleukin-6 family of cytokine
receptors, that has been shown to promote cell survival and compensatory
hypertrophy in the presence of an apoptotic stimulus in vitro (120). When
gp130 knockout mice were exposed to acute pressure overload, they
developed dilated cardiomyopathy accompanied by massive myocyte
apoptosis, whereas the control mice exhibited compensatory hypertrophy
(120). This suggests that gp 130 mediates a myocyte survival pathway that acts
by blocking the onset of myocyte apoptosis during pressure overload. It also
suggests that cardiac myocyte apoptosis and hypertrophy may be activated by
common signaling pathways (120). In this way the balance between apoptotic
and hypertrophic pathways determines whether chamber dilatation will occur
(121).
Despite the large number of studies of apoptosis in heart failure, we do not yet
know with certainty if myocyte apoptosis contributes to the progression of
human heart failure, or if it is a homeostatic process that serves to dismantle
dysfunctional myocytes in an orderly manner (50). The presence of
cardiomyocyte apoptosis in heart failure however, has raised hopes that
inhibition could prevent or slow down the loss of contractile cells (122).
Prevention of apoptotic myocyte loss may be directed at several levels. Therapy
directed at the adverse pathophysiologic condition of heart failure includes
ACE-inhibitors (99) and β-blocking agents (101). Therapy inhibiting the
intracellular regulatory mechanisms of apoptosis can be directed at the Bcl-
2/Bax ratio or death domain proteins. Finally, therapy can be directed at the
effector pathways of apoptosis like the caspases.  Several important questions
still need to be answered considering the use of anti-apoptotic therapy in heart
failure. The beneficial effect of ACE-inhibitors and β-blocking agents has been
repeatedly demonstrated. However, it has not been shown whether direct
inhibition of apoptosis could delay or prevent the development of heart failure.
Also, anti-apoptotic therapy for heart failure may not apply to all types of heart
failure. It is also a question if the immediate benefits of rescuing myocytes from,
for example, TNF-induced apoptotic cell death, may be mitigated by the
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unaffected negative inotropic effect of TNF that seems to be independent from
its pro-apoptotic activity (122). It is possible that inhibiting apoptosis may
simply result in a shift towards necrosis, which may have more deleterious
effects on neighbouring cells and ultimately a worse outcome (74). Importantly,
the safety of direct anti-apoptotic therapy has not been tested. Given the role of
apoptosis in the removal of premalignant cells and the downregulation of
immune-effector cells, directly blocking apoptosis may be associated with
significant deleterious consequences like lymphoma and autoimmune disorders
(74). Therefore, a lot of research has to be performed in this area, before anti-
apoptotic therapy can be introduced in patients with heart failure.
Cytokines
As mentioned above, cytokines are thought to play an important role in heart
failure as mediators of cardiomyocyte hypertrophy and cardiomyocyte
apoptotic cell death. Cytokines are soluble peptides, which mediate cell-to-cell
interactions via specific cell surface receptors and regulate the activation,
differentiation, growth, death or acquisition of effector functions of the immune
system (123). In addition, they mediate effects of the cells of the immune
system on other cells and tissues. They usually act in an autocrine (on the cell
that produced them) or paracrine (on cells close by) manner. Well over 100
different human cytokines have now been identified (Table 2). They act by
binding to specific receptors at the cell membrane, setting off a cascade that
leads to induction, enhancement or inhibition of a number of cytokine-
regulated genes in the nucleus (124).
Name abbreviation examples
interleukins IL IL-1β, IL-2, IL-6, IL-10
interferons IFN IFNα, IFNβ, IFNγ
tumor necrosis factors TNF TNFα, TNFβ, FasL
growth factors GF NGF, EGF
colony stimulating factors CSF M-CSF, G-CSF
chemokines - RANTES, MCP-1
Table 2. Some common cytokines
In this overview of the cytokines mainly TNFα and FasL will be discussed,
because these cytokines are especially thought to have a pathogenic role in
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heart failure.
The biologic effects of cytokines seem to be determined primarily by the local
level in the body compartment in which they are produced and not by the
serum levels. However, continuous infusion of TNFα in a study in rats, resulted
in a time dependent, partially reversible depression of left ventricular function
(125). Elevated circulating levels of TNFα in patients with severe heart failure
have been repeatedly reported (56, 57), especially in cachectic patients (126).
The interpretation of these results however, is hampered by the natural
variability of circulating cytokine levels (127). Analysis of circulating levels of
cytokines and their cognate receptors in 1200 patients with advanced heart
failure, enrolled in the Vesnarinone trial, showed that increased levels of TNFα,
interleukin-6, and the soluble TNF receptors were associated with increased
mortality (128). TNFα mRNA and TNFα protein have also been demonstrated
in explanted hearts from patients with dilating cardiomyopathy or ischemic
heart disease undergoing heart transplantation (129). Transgenic mice with
cardiomyocytes producing TNFα all died of heart failure, supporting a causal
role for TNFα in the pathogenesis of human cardiac disease (130). Furthermore,
in animal studies, chronic ß-adrenergic stimulation led to a significant increase
in mRNA and protein expression of TNFα throughout the myocardium (131). A
provisional study with a specific TNFα antagonist (Etanercept) in 47 heart
failure patients resulted in a significant improvement in ejection fraction and a
trend toward improvement in functional status, further underlining the possible
role of TNFα in the progression of heart failure (132). However, a large study
with this TNFα antagonist was recently discontinued because of lack of benefit.
TNFα is synthesized as a large inactive protein, which is activated by a tissue
metalloproteinase called TNFα converting enzyme (TACE) (133). Like TNFα,
TACE has been demonstrated in cardiomyocytes of patients with dilated
cardiomyopathy (DCM) (134).
Two types of TNFα receptors have been identified: a 55-kDa (TNFR1) and a 75-
kDa (TNFR2). Both receptors are widely expressed on human cells, including
adult cardiomyocytes (135). In heart failure patients TNF receptor proteins were
decreased in comparison to non-failing hearts, possibly correlating with
increased levels of soluble TNF receptors in the serum as a consequence of
receptor shedding (129). The soluble receptors are able to bind circulating
TNFα. In this way the cytotoxic effects of TNFα may be neutralized. Binding of
TNFα to cardiac TNFR1 results in a negative inotropic effect in cardiomyocytes
(135). This myocardial depression can be the result of direct alterations in
intracellular calcium homeostasis leading to decreased levels of peak
intracellular calcium during the systolic contraction (136) or through enhanced
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activity of nitric oxide (NO) synthase in the myocardium (137). In addition,
TNFα effectively uncouples the beta-adrenergic receptors from adenyl cyclase
via an effect on the G inhibitory protein (138). Induction of apoptotic cell death
by TNFα is also predominantly mediated by TNFR1 (139). TNFR2 is thought to
contribute to TNFα toxicity by recruiting TNFα for interaction with TNFR1. In
this way a lower concentration of TNFα is needed for TNFR1 signal
transduction (135).
Another molecule belonging to the TNF family is Fas-ligand (FasL). Binding to
its receptor Fas, like TNFα, results in apoptosis of the Fas bearing cell (140).
This is an important mechanism in the down-regulation of immune reactions as
well as in T cell-mediated cytotoxicity (141). After myocardial ischemia this
interaction is also thought to be directly involved in cell death (142). A study in
rats showed constitutive expression of FasL and upregulation of Fas in relation
to diastolic but not systolic wall stress. This did not result however, in
enhanced cardiomyocyte apoptosis (143).
This suggests that other regulators of cardiomyocyte cell death have to be
present. It is here that FLICE-inhibitory protein (FLIP) probably plays an
important role because it can inhibit apoptosis induced by all known human
death receptors and is highly expressed in the heart (115).
Aim of the thesis
The main purpose of this thesis was to study the role of left ventricular
mechanical support in end-stage heart failure. In addition, the availability of
myocardial tissue from patients with end-stage heart failure, at two points in
time, during the implantation of the LVAD, and after support, at the time of
heart transplantation, offered the unique opportunity to investigate some
fundamental aspects of end-stage heart failure in man.
As heart transplantation can only be used for a small number of heart failure
patients, we were especially interested if a LVAD can be successfully used as
an alternative to heart transplantation. Furthermore, we were interested to find
out to what extent mechanical support with a LVAD might result in myocardial
recovery.
In chapter 2 the clinical results of the HeartMate LVAD as a bridge to heart
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transplantation in our center are presented. Chapter 3 deals with the exercise
performance of patients while on a LVAD in comparison with the situation after
heart transplantation, to examine if a LVAD can be an alternative to heart
transplantation, regarding exercise performance. In chapter 4 recovery of
cardiac histology is reported during mechanical support with a LVAD in
patients with end-stage heart failure. For this purpose the contractile
myofilaments are analyzed using immunohistochemistry. Chapter 5 deals with
cardiomyocyte apoptotic cell death in clinical heart failure and some of the
mediators and receptors involved, and the effect of LVAD support on it. In
chapter 6 the morphology of the contractile myofilaments of the left ventricle is
compared with that of the right ventricle and the interventricular septum, using
large transmural biopsies and small biopsies taken with a bioptome. This was
done to assess if right ventricular endomyocardial biopsies may be used to
monitor recovery of cardiac histology in the left ventricle.
Chapter 7 contains a general discussion.
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Abstract
OBJECTIVE- To evaluate the use of left ventricular assist devices (LVAD) as
bridge to heart transplantation (HTx) in patients with end-stage heart failure.
METHOD- Between March 1993 and December 2001, 38 patients with
refractory end-stage heart failure underwent HeartMate LVAD (Thoratec,
Pleasanton Calif.) implantation.
RESULTS- 33 of the 38 patients (87%) survived the implantation and
perioperative period. There were 5 perioperative deaths (13%), 2 of right
ventricular failure, 2 as a result of bleeding and 1 probably due to septic shock
at the time of LVAD implantation. Three patients (9%) died late in the
postoperative period due to septic shock, mechanical failure of the device and
a cerebral embolus resulting from LVAD endocarditis, initiated by an acute
cholecystitis. Twelve patients (32%) had one or more infectious episodes
during long-term assist, of which 1 patient died. Four patients are still on the
device, waiting for heart transplantation. Twenty-six patients (76%) underwent
HTx after 206±129 days of support.
CONCLUSION- These results show the efficacy of LVAD support as a bridge to
heart transplantation in patients with end-stage heart failure. Major long-term
complications are infections and mechanical failure of the device.
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Introduction
In the treatment of patients with end-stage heart failure, heart transplantation is
still the only option that provides both a better life expectancy and a
substantially better quality of life 1,2. It mostly results in a dramatic improvement
in general wellbeing and in exercise performance 3,4. However, since the start of
heart transplantations in the Netherlands in 1984 the number of procedures has
been limited due to shortage of suitable donor hearts. Every year the heart
transplant centers in Utrecht and Rotterdam together perform 40-50 heart
transplants. This number has been fairly stable during the last decade, despite all
measures to improve donation and despite the tendency to accept hearts from
older donors.
The low number of heart transplantations is in sharp contrast to the growing
number of patients with end-stage heart failure 5. This discrepancy has resulted in
long waiting times and a high (15-20%) mortality on the transplantation waiting
list. Moreover, many potential transplant candidates not even make it to the
waiting list, because of acute hemodynamic deterioration. To reduce this high
mortality rate, mechanical circulatory support can play an important role as a
bridge to transplantation. Implantable left ventricular assist devices like the
HeartMate (Thoratec, Pleasanton Calif.) and the Novacor (WorldHeart, Ottawa)
are the most suitable devices as bridge to transplant, because they can support the
failing heart for months or even years 6-10.
The Heart Lung Center Utrecht (HLCU) started a bridge to transplantation program
in 1993 using the implantable HeartMate pneumatic and later the vented electric
left ventricular assist device.
In this article the results of 8 years experience with this device are presented.
Methods
Description of the HeartMate®  device and mode of implantation.
The HeartMate® left ventricular assist system (LVAS) consists of an implantable
pneumatic (IP) or a vented electric (VE) left ventricular assist device (LVAD) (fig 1).
The pump consists of a titanium housing with a flexible Biomer polyurethane
diaphragm bonded to a rigid pusher plate. The diaphragm divides the pump in
two halves: a blood chamber and an air chamber in case of the IP system or an
electrical motor chamber in case of the VE system. The air chamber of the IP
system is connected to an external console by a transcutaneous driveline. By
delivering programmed pulses of air the console provides the displacement of the
diaphragm propelling the blood through an outflow graft into the arterial
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circulation. Both the outflow and inflow graft contain porcine xenograft valves,
providing uni-directional flow. Differences in air pressure between this closed
system and the ambient air are equalized by manually venting the system on the
console, which also has a display continuously showing information about stroke
volume, filling status and pump rate.
Figure 1: Schematic diagram of the HeartMate VE left ventricular assist device. The inflow
canula is implanted in the left ventricular apex. The outflow graft is connected end to side
to the ascending aorta. The transcutaneous skinline is connected to the controller.
In case of a VE system the pump is electrically driven and continuously vented
through an almost identical driveline connected to a small controller and
energized by rechargeable batteries.  The LVAD has a maximal stroke volume of
83 ml and a maximal beat rate of 120 beats per minute. The pump can function in
a fixed mode or in an automatic mode, allowing the device to vary its flow
dependent on the left ventricular filling volume.
The unique feature of the HeartMate® blood pump is the blood-contacting surface.
These textured biomaterials are to promote the formation of a thin, well-adhered
pseudointimal lining on the inner side of the pump. This non-thrombogenic
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neointimal layer reduces the need for anticoagulation, as are the porcine
xenografts; only 80 mgr. of aspirin a day is required for antithrombotic
prophylaxis.
Implantation of the device is accomplished through a median sternotomy and
laparotomy. The pump is implanted in the left upper quadrant of the abdomen,
intra-or extraperitoneally. The inlet canula connects the apex of the left ventricle
to the pump, while the outlet canula is connected end to side to the ascending
aorta using a Dacron® vascular graft. (Fig 1). Both canulae pass the diaphragm.
Since 1997 the driving console has been replaced by a smaller, portable one
(HeartPak) (fig 2) which is charged by exchangeable batteries and offers the
patients a better and more extended range of mobility.
Patients.
From March 1993 to December 2001, 38 patients, (34 males, 4 females, mean
age 38±13 years, range 16-62 years) received the HeartMate® LVAD as a
bridge to heart transplantation. Indication for implantation was cardiogenic
shock refractory to drug treatment in all cases (table 1). Dilating
cardiomyopathy was the underlying cause in 23 patients (60%), ischemic heart
disease in 15 (40%).
Pre LVAD all patients were on high-dose intravenous inotropic medication
(dopamine, dobutamine and milrinon) and 16 patients were also supported by
an intra-aortic balloon pump. An external ventricular assist device had been
implanted in 3 cases (1 Hemopump and 2 Abiomed BVS 5000). The pneumatic
HeartMate IP was used in 32 patients, the electrical HeartMate VE in 6.
Statistical analysis
Data are presented as the mean ± SD. Statistical analysis was performed with
two-tailed paired Student t test. A p-value<0.005 was considered significant.
Results.
In this group of 38 patients, 33 survived the implantation and early postoperative
period (87%). Five patients died in the first 30 days post implant (peri-operative
mortality 13%), 3 patients (9%) died late in the postoperative period  (Table 2).
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Table 1. Characteristics of LVAD patients at the time of implantation (n=38)
Male / Female
Age (yr.)
DCM / IHD
LVEF (%)
Cardiac Index (L/min/m2)
MAP (mm Hg)
RAP (mm Hg)
PCWP (mm Hg)
PVR (dyne sec cm-5)
TPG (mm Hg)
IABP / other support
Mean duration support (days)
    34 / 4
    38 ± 13
    23 / 15
    14 ± 5
    2.0 ± 0.7
    62 ± 11
    13 ± 7
    24 ± 7
    196 ± 94
     9 ± 4.2
    16 / 3
    172 ± 140
Figure 2: The three models of the HeartMate Left Ventricular Assist System. The
Implantable Pneumatic system with the original console and with the portable console
(HeartPak), and the Vented Electric device.
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Table 2. Patient mortality and cause of death (n=8)
Patient Sex Age Survival/days Cause of death
# 3 M 42 133 Mechanical failure
# 5 M 20 3 RVF
# 6 F 52 8 RVF
# 10 M 62 0 Bleeding
# 18 M 38 435 Cerebral embolus
# 23 M 49 35 Septic shock
# 25 M 25 6 Bleeding
# 30 M 24 0 Septic shock at time of
implantation
RVF: right ventricular failure
Mean duration of support for the 38 patients was 172±140 days with a longest
duration of 557 days and a cumulative experience of 6522 days (nearly 18 years).
Successful implantation of the HeartMate® LVAS resulted in an immediate
improvement of the hemodynamic situation in all patients. Cardiac index
increased from 2,0±0,7 l/min/m2 pre implantation to 3,0 ± 0,5 l/min/m2  24 hours
post transplantation (p < 0.0001).
Renal and hepatic function normalized within 6 weeks (Table 3). Use of the
mechanical pump device did not cause hemolysis (normal serum Hb and
haptoglobin levels), or thrombocytopenia (platelet count 211±81.109 /L pre-
implantation versus 289±81.109 /L, 6 weeks post implantation) in any of the
patients.
Four patients are still on the device. Of the remaining 34 patients, 26 (76%)
underwent heart transplantation, after an average of 206±129 days on the device.
At the time of transplantation all patients were in NYHA functional class 1 and
were fully mobilized. After an intensive training and instruction program seven
patients have been discharged from the hospital awaiting heart transplantation at
home.
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Table 3. Hepatic and renal function pre and post implant  HeartMate (n=31)
Variable mean±SD
pre implant
Mean±SD
6 weeks post
implant
p-value
Creatinin (µmol/l)
Tot.bilirubin (mmol/l)
ASAT (U/l)
ALAT (U/l)
159 ± 79
27 ± 18
103 ± 129
99 ± 114
74 ± 27
14 ± 10
25 ± 9
23 ± 13
P<0.0003
p<0.01
p<0.03
p<0.01
COMPLICATIONS
Right ventricular failure (RVF)
RVF early after implantation occurred in 12 patients (32%). All but 3 patients were
successfully treated with positive inotropic agents, vasoactive agents and optimal
oxygenation. In three patients temporary support of the failing right ventricle was
necessary using an external device (Abiomed®). Weaning of this device was only
successful in one single case, 2 patients died in the postoperative course due to
complications related to right ventricular failure (air embolism and a hypotensive
cerebral infarction).
Bleeding.
Severe postoperative bleeding requiring blood transfusion and reoperation
occurred in 5 patients. Two of these died. One patient died due to multi-organ
failure after a complicated surgical procedure with long duration of extra-
corporeal circulation. The other patient died due to an irreparable disrupture of
the left ventricular apex-inlet canula connection, 7 days after implantation.
Thrombo-embolic complications.
Thrombo-embolic events occurred in only three patients, but resulted in death in
two. One patient suffered a massive cerebral infarction resulting from LVAD
endocarditis 418 days post implant. The LVAD endocarditis probably originated
from an acute cholecystitis. Another fatal thrombo-embolic event occurred due to
mechanical failure of the control unit. The third patient suffered episodes of
amaurosis fugax and recurring abdominal pain suggestive of embolic renal
disease, for which oral anticoagulation was successfully installed.  The overall
thrombo-embolic complication rate was 7.9 % or 0.014 events per patient month,
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despite the use of only low dose aspirin as anti-thrombotic prophylaxis in all
cases. If the patients with the device malfunction and the LVAD endocarditis are
excluded, the thrombo-embolic complication rate was 2.6 % or 0.005 events per
patient month.
Device related infections
Twelve patients (32%) had driveline and pocket infections, primarily
staphylococcus aureus. Nine of these patients had positive blood cultures.
Treatment in all patients consisted of intravenous antibiotics in combination
with local treatment. One patient died as a result of septic shock caused by
coagulase negative Staphylococcal infection 45 days after LVAD implantation.
In 5 patients surgical treatment was necessary consisting of pocket exploration
and transposition of an abdominal rectus muscle flap. One patient was kept on
long term antibiotic treatment under suspicion of endocarditis of the porcine
xenografts in the device. Explantation of the device, at the time of heart
transplantation, however, did not reveal signs of endocarditis.
Mechanical complications
Few minor mechanical defects such as driveline electrical wire fractures,
display dysfunction, and driver sensor dysfunction occurred, not causing pump
function to cease.  Major dysfunction of the device occurred in 2 patients. In
one case pump function ceased because the pneumatic driving console got
jammed, resulting in the nursing staff having to drive it manually for a short
period. The console had to be replaced and the patient did not suffer any
adverse effects. Mechanical dysfunction of a pneumatic device in a second
patient however happened to be fatal (patient # 3 in table 2). A combination of
a failing sensor and the vent valve not closing properly after a routine venting
procedure at 19 weeks’ post implantation, resulted in a low stroke volume,
while the patient was asleep and the devices low flow alarm not going off, due
to the failing sensor. This low flow state caused the patient to suffer a fatal
stroke due to cerebral embolism originating from an intraventricular thrombus.
Surgical complications during heart transplantation
The presence of a LVAD resulted in a more complex heart transplant
procedure. In five patients (19%) this lead to increased bleeding requiring re-
operation. In one patient a hepatic laceration due to adhesions had to be
oversewn. The abdominal wall could be closed primarily in all patients; the
diaphragm had to be reconstructed in some.
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Discussion.
The use of implantable left ventricular assist devices as bridge to transplantation
for heart transplant candidates, who deteriorate while waiting for a donor heart, is
now widely accepted 11-13. The results are very encouraging, especially
considering the poor condition of the patients at the time of LVAD implantation,
who were facing imminent death. This treatment not only leads to increased
survival, but also to complete restoration of renal and liver function and
impressive improvement of functional class, comparable to the situation after
heart transplantation, as we have reported previously 4.
Our preference for the HeartMate LVAD over other implantable devices was
based on its blood-contacting inner surfaces, promoting the formation of a
biological lining, not necessitating the use of anticoagulants and diminishing the
risk of thrombo-embolic complications14. This study and studies by others confirm
the low risk for thrombo-embolism with this device 7, 12, 14, 15.
The overall patient survival until transplantation of 79 % in this study is promising,
considering the long mean duration of support (172±140 days). The latter is the
reflection of the long waiting time for heart transplantation in our transplant
program.
Given this, our policy in the last 2 years has been to discharge patients from the
hospital while on the device after they had been fully recovered and after they
had been extensively trained to use the device16. This requires good cooperation
of the patient and intensive follow-up and support facilities of the hospital.
Considering survival in this study one has to bear in mind the young mean age of
the patients, which is younger than in other published studies 6-8.
Right ventricular failure has been reported a serious problem after LVAD
implantation with risk of air-embolism during the implantation procedure and
inadequate filling of the device resulting in low output thereafter. This problem is
inherent to the fact that only the left ventricle is supported and it did occur in
almost one third of the patients in this study, as has been reported by others 12, 17,
18. Predictors of right ventricular failure are high right atrial pressure, high
transpulmonary gradient and an acute decrease in pulmonary artery pressure with
LVAD implantation17. Growing experience and better patient selection is probably
the explanation that no fatalities due to RVF occurred in the second half of the
study.
Device-related infections, partly due to the presence of transcutaneous drivelines
are reported to be another major problem 19-22. The rate of 32 % device-related
infections in our patients corresponds to reports in literature. In two patients an
infectious episode turned out to be fatal. Therefore, the infection problem needs
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careful attention. Totally implantable devices with transcutaneous energy
transmission, which are currently being clinically investigated, may decrease the
risk of driveline related infections.
There were various mechanical problems, especially of the pneumatic driving
consoles, but except for one case, these were not fatal. The need for continuous
support by an experienced technical department, however, proves to be
increasingly mandatory.
In conclusion, this study shows promising results using the HeartMate IP and VE
LVAD as a bridge to transplantation in patients with end-stage heart failure. The
main drawbacks are the mechanical complications and the high risk for infections,
partly related to the transcutaneous driveline. Future devices may diminish these
problems, allowing longer periods of event-free support. Based on the present
experience and future technical improvements, LVAD’s may not only be used as a
bridge to transplantation, but also as an alternative to transplantation. The recently
reported results of the Randomized Evaluation of Mechanical Assistance for the
Treatment of Congestive Heart Failure (REMATCH) Study Group, showing a
significant improval of survival one year after LVAD implantation vs. the medical-
therapy group, support this idea 23.
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Abstract
OBJECTIVES-  We sought to study exercise capacity at different points in time
after left ventricular assist device (LVAD) implantation and subsequent heart
transplantation (HTx).
BACKGROUND- The lack of donor organs warrants alternatives for
transplantation.
METHODS- Repeat treadmill testing with respiratory gas analysis was
performed in 15 men with a LVAD. Four groups of data are presented. In group
A (n=10) the exercise capacities at 8 weeks and 12 weeks after LVAD
implantation were compared. In group B (n=15), the data at 12 weeks are
presented in more detail. In group C (n=9), sequential analysis of exercise
capacity was performed 12 weeks after LVAD implantation and at 12 weeks
and one year after HTx. In group D, exercise performance one year after HTx in
patients with (n=10) and without (n=20) a previous assist device was
compared.
RESULTS- In group A, peak oxygen consumption (VO2) increased from
21.3±3.8 to 24.2±4.8 ml/kg/min (p<0.003), accompanied by a decrease in
peak minute ventilation/carbon dioxide production (VE/VCO2 ) (39.4±10.1 to
36.3±8.2; p< 0.03). In group B Peak VO2 12 weeks after LVAD implantation
was 23.0±4.4 ml/kg/min.
In group C, levels of peak VO2 12 weeks after LVAD implantation and 12
weeks and one year after HTx were comparable (22.8±5.3, 24.6±3.3 and
26.2±3.8 ml/kg/min, respectively; p=NS). In group D, there appeared to be no
difference in percent predicted peak VO2 in patients with or without previous
LVAD (68±13 % vs. 74±15 %; p<0,37), although, because of the small
numbers, the power of this comparison is limited (0,45 to detect a difference of
10%).
CONCLUSION- Exercise capacity in patients with a LVAD increases over time;
12 weeks after LVAD implantation, VO2  is comparable to that at 12 weeks and
one year after HTx. Previous LVAD implantation does not seem to adversely
affect exercise capacity after HTx.
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Introduction
Aging of the population and prevention of premature death from ischemic heart
disease by improved medical and surgical management have led to a growing
incidence of heart failure. Improved medical therapy for chronic heart failure
has further reduced mortality, thereby expanding the number of patients with
heart failure (1). Heart transplantation (HTx) is the ultimate treatment option for
end-stage heart failure. However, due to a shortage of donor hearts, this therapy
can be offered to only a very small number of patients. Therefore, mechanical
circulatory support of the failing heart has been suggested as an alternative to
HTx. To date, two types of internal left ventricular assist devices (LVADs) are
available: the TCI HeartMate (Thermo Cardiosystems Inc., Woburn,
Masschusetts) and the Novacor (World Heart Corporation, Ottawa, Canada),
both mainly used as a bridge to transplantation.  In selected patients the results
are excellent with approximately 75 % successful bridging to transplantation
and LVAD support time lasting up to three to four years (2,3,4). Based on the
growing experience with these devices, it seems realistic to use the LVAD as an
alternative to HTx or long-term bridging (in terms of years) to transplantation in
youngsters.
One of the prerequisites for permanent or semi-permanent assisting is that
exercise performance, although not normal, should be adequate for daily life
activities, as is the case after HTx. Until now, few studies are available
evaluating exercise capacity after LVAD implantation (5-10). Most studies are
based on small numbers of patients from different institutions, with divergent
postoperative care, rehabilitation programs and exercise testing protocols,
which may limit direct comparison of the results. Only one study compares
exercise performance in patients after LVAD implantation and following HTx
(6).  Data on the ventilatory response to exercise and the progress of exercise
performance after long-term LVAD implantation have not yet been reported.
Therefore, we performed repeated exercise testing with respiratory gas analysis
in a cohort of consecutive patients with end-stage heart failure with an assist
device and after HTx. To find an effect of LVAD implantation on exercise
performance after HTx, a comparison was made between a group of post-
transplant patients with and without a previous LVAD.
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Methods
Patients with a LVAD.
Fifteen consecutive male patients (age 37±12 years  [mean ± SD]) with
refractory end-stage heart failure treated in our center with a pneumatic LVAD
(TCI HeartMate) were included in the study (Table 1). All patients were in
critical hemodynamic condition, with a mean ejection fraction of 13±5 %,
cardiac output 3.2±0.5 l/min and a mean arterial pressure of 62±9 mm Hg,
despite high doses of inotropic support and sometimes intra-aortic balloon
counterpulsation. All patients were eligible as transplant candidates or were
already on the waiting list. After LVAD implantation, patients could be
mobilized at an early stage and participated in an intensive rehabilitation
program supervised by a physical therapist, aimed at dynamic exercise, strength
and endurance (see Appendix).
Table 1. Characteristics of patients with a left ventricular assist device
Male 15
Age (y) 37±12
Length (cm) 179±9
Weight (kg) 71±8
Duration (mo) 4.7±5.8
DCM 8
IHD 7
LVEF (%) 13±5
CO (l/min) 3.2±0.5
MAP (mmHg) 62±9
PVR (d.s.cm-5) 162±54
Assist time (days) 181±125
 Duration = time between onset of heart failure symptoms and implantation of LVAD
(months);
Heart transplant patients.
A cohort of 20 consecutive male heart transplant recipients (mean age 52±10
years) without a previous HeartMate was used for comparison. All patients
were in NYHA functional class I.
Study design.
Maximal exercise capacity 8 weeks after LVAD implantation was compared
with that 12 weeks after implantation (Group A, n=10). All patients performed
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an exercise test 12 weeks after implantation (Group B, n=15).To support the
hypothesis that exercise performance, with an assist device, is sufficient and
comparable to that after HTx, we performed a sequential analysis of exercise
capacity 12 weeks after LVAD implantation, as well as 12 weeks and one year
after HTx in the same patients (Group C, n=9). Finally, exercise capacity one
year after HTx in the post-LVAD group was compared to that in a cohort of
transplant patients without a previous assist device (Group D).
Exercise studies.
All patients underwent treadmill exercise testing using a 2-min staged modified
Naughton protocol or a modified Bruce protocol. Continuous breath-by-breath
respiratory gas analysis (Oxycon, Jaeger inc, Breda, Netherlands) was
performed. Measurements included heart rate, blood pressure, oxygen
consumption (VO2), carbon dioxide production (VCO2), minute ventilation (VE)
and respiratory exchange ratio (RQ=VCO2/VO2). Peak VO2 was defined as the
average VO2 during the last minute of exercise and is expressed as ml/kg/min as
well as ml/min. In addition, to correct for differences in age among the study
groups, the percentage of the predicted values was calculated according to
Jones (11,12). Oxygen consumption at the anaerobic threshold (AT) was
identified as the oxygen uptake before the systematic increase in the ventilatory
equivalent for oxygen (VE/VO2), without a concomitant increase in the
ventilatory equivalent for carbon dioxide (VE/VCO2), together with the V-slope
method (13,14). The ventilatory response to exercise was defined as VE/VCO2
at peak exercise (15). All tests for patients with a LVAD were performed in the
automatic mode of the device, allowing LVAD output to follow an increase of
venous return.
Statistical analysis.
Data are presented as the mean ± SD. Statistical analysis was performed with
two-tailed paired and unpaired Student t tests, as appropriate. For the
sequential analysis of the three exercise tests in the same patients, repeated
measures analysis of variance (ANOVA) was used. If relevant, 95% confidence
intervals (CIs) of differences were calculated. A p-value < 0.05 was considered
statistically significant. All analysis were performed using SPSS version 8.0 for
Windows.
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Results
All 15 patients with a LVAD completed exercise testing 12 weeks after
implantation. In 10 of these patients, a test at eight weeks after implantation
was available. There were two late deaths: one due to device failure 133 days
after implantation and the other due to repeated cerebral embolism 432 days
after implantation. Thirteen patients (87%) were successfully bridged to HTx
after a mean duration of support of 181±125 days (range 71to 455 days). Early
after HTx, three patients died: one patient died from  peri-operative bleeding
and two died from intractable infections. One patient was not fit to perform an
exercise test 12 weeks after HTx due to pneumonia at that time. Thus, 9
patients completed exercise testing 12 weeks after LVAD implantation, as well
as 12 weeks and one year after HTx (Fig.1).
Figure 1. Flow diagram of patients with a left ventricular assist device (LVAD) and
exercise tests.
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Before LVAD implantation, all 15 patients were in NYHA functional class IV.
After LVAD implantation, all patients demonstrated an impressive improvement
in general well-being and complete recovery of organ function. Eventually, all
cardiac medication could be stopped, even when previous right ventricular
failure in the LVAD group was present.  Only aspirin, 80 mg/day, was given to
prevent thromboembolic complications.
Table 2. Comparison of exercise performance 8 and 12 weeks
after LVAD implantation in the same patient (n=10).
8 weeks 12 weeks
peak VO2(ml/kg/min) 21.3±3.8 24.2±4.8*
% predicted 53±9 60±10*
peak VO2  (ml/min) 1438±286 1671±317*
% predicted 47±7 54±6*
AT (ml/kg/min) 14.8±2.2 15.8±4.0
VE/VCO2 39.4±10.1 36.3±8.2  †
RQ 1.2±0.1 1.2±0.1
Pumprate (min-1) 108±19 115±18
Pumpflow (l/min) 7.2±1.1 7.6±1.1
* p≤ 0.003 12 weeks post LVAD versus 8 weeks post LVAD.
† p<0.03 12 weeks post LVAD versus 8 weeks post LVAD.
Group A: Comparison of  exercise capacity  8 and 12 weeks after LVAD
implantation (Table 2). Peak VO2 increased from 21.3±3.8 at 8 weeks to
24.2±4.8 ml/kg/min at 12 weeks after implantation (p< 0.003; 95% CI of the
difference: 4.7 to 1.3). Furthermore, the ventilatory response to exercise
(VE/VCO2) decreased from 39.4±10.1 at 8 weeks to 36.3±8.2 at 12 weeks
after implantation (p<0.03; 95% CI of difference 0.4-5.8).
Group B:Exercise performance 12 weeks after LVAD implantation (Table 3).
Twelve weeks after LVAD implantation, all patients were in NYHA functional
class I (apart from the limitations imposed by the drive lines and the console of
the device).  Peak VO2 averaged 23.0±4.4 ml/kg/min. (range 17.2 to 32.1), or
58±9% of the predicted value (range 43 to 80%), sufficient for normal
activities of daily life (14). There was no difference in peak VO2  between
patients with ischemic heart disease (n=7) and those with dilated
cardiomyopathy (n=8) (21.6± 2.6 vs. 24.2 ± 5.4 ml/kg/min).
Chapter 3
68
Table 3. Exercise performance 12 weeks after LVAD
implantation (n=15)
age (y) 37±12
peak VO2  (ml/kg/min) 23.0±4.4
% predicted 58±9
peak VO2  (ml/min) 1620±301
% predicted 54±8
AT (ml/kg/min) 15.4±3.7
RQ 1.2±0.1
Group C: Sequential analysis of exercise performance in 9 patients  12 weeks
after LVAD implantation and then at 12 weeks and one year after HTx (Table
4, Fig. 2). In this group, three exercise tests were compared by repeated
measures ANOVA. Peak VO2 demonstrated some improvement, although
statistically insignificant: 22.8±5.3, 24.6±3.3 and 26.2±3.8 ml/kg/min,
respectively (p=0.26; 95% CI of difference between 12 weeks after LVAD and
12 weeks after HTx: -1.91to 5.47). Expressed as percentage of the predicted
value, these were 58±12%, 63±10% and 69±13%, respectively (p=NS). The
patients’ AT increased from 14.4±4.0 ml/kg/min with a LVAD to 15.9±3.3 and
18.7±2.5 ml/kg/min 12 weeks and one year after HTx, respectively (p= NS).
The ventilatory responses (VE/VCO2 at peak exercise) 12 weeks after LVAD
implantation and 12 weeks and one year after HTx were not different
(37.2±7.8, 33.0±4.4 and 33.7±4.7, respectively).
 Group D: Exercise capacity one year after HTx with and without a previous
LVAD. Because of the large difference in the mean age between both groups,
these data were only analyzed as percentage of predicted peak VO2. Without a
previous assist device (n= 20), peak VO2 one year after HTx was 74±15%
versus 68±13% of the predicted value in patients with a previous LVAD
(n=10; p= 0,37 [NS]; 45% power to detect a difference of 10% with a two-
sided significance of 0,05).
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Table 4. Sequential analysis of exercise performance in nine patients at 12 weeks after
LVAD implantation and then at 12 weeks and one year after heart transplantation
12 weeks
after LVAD
12 weeks
after HTx
1 year
after HTx
peak VO2
 (ml/kg/min)
22.8±5.3 24.6±3.3 26.2±3.8
% predicted 58±12 63±10 69±13
peak VO2
 (ml/min)
1524±326 1722±357 1988±513
% predicted 51±7 57±10 67±13
AT (ml/kg/min) 14.4±4.0 15.9±3.3 18.7±2.5
VE/VCO2 37.2±7.8 33.0±4.4 33.7±4.7
RQ 1.2±0.1 1.1±0.1 1.1±0.0
Figure 2. Peak VO2 (ml/kg/min) in nine patients 12 weeks after LVAD implantation and
then at 12 weeks and one year after HTx (p = NS by repeated measures analysis of
variance).
Discussion
The results of this study suggest that exercise performance after implantation of
a TCI HeartMate LVAD in a group of patients with end-stage heart failure, who
underwent intensive postoperative rehabilitation, is sufficient for activities of
normal daily life. An increase in maximal exercise performance from 8 to 12
weeks could be demonstrated (Table 2), most likely due to postoperative
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convalescence and systematic strenuous training. One may speculate that
longer assist times will result in an even better exercise performance. This
improvement in exercise performance over time was accompanied by a
significant decrease in the ventilatory response to exercise (VE/VCO2). This
variable is often increased in patients with severe heart failure and is
considered an independent and even better prognostic marker than  reduced
peak VO2 (15,16). Twelve weeks after implantation, peak VO2 averages 23.0
ml/kg/min, compatible with Weber class A(17). Sequential analysis of exercise
performance in nine patients at 12 weeks after LVAD implantation and then at
12 weeks and one year after HTx demonstrated  similar peak VO2, AT and
VE/VCO2 values. Therefore, apart from the limitations imposed by the operating
console and the drive line of the HeartMate, activities with placement of a
LVAD are expected to be comparable to those after HTx.
Furthermore, exercise performance of patients one year after HTx with a
previous LVAD approximates  that of post-transplant patients without a
previous LVAD. This indicates that the impact of pre-transplant LVAD, per se,
implying a thoracotomy and laparotomy with a diaphragmatic incision through
which the inlet conduit of the HeartMate is passed, together with the potential
detrimental effects of  cardiopulmonary bypass, does not appear to lead to late
consequences in terms of  diminished exercise capacity. However, the
presence of  a LVAD certainly complicates the transplant procedure and may
lead to excessive bleeding. This may have contributed to the peri-operative
death of one of the patients. In contrast, the excellent general condition before
HTx, in all probability, is an advantage for post-transplant rehabilitation,
although this could not be translated in terms of a shorter hospital stay after
HTx.
Comparison with previous studies. Our results seem to diverge from those of
other studies on this subject. In the Experience with left Ventricular Assist
Device with Exercise (EVADE) trial (6), peak VO2 one to three months after
LVAD implantation was reported to be 14.5±3.9 ml/kg/min, compared with
17.5 ±5.0 ml/kg/min after HTx. Mancini et al.(7)compared exercise
performance in 20 patients with a LVAD with that of heart failure patients
without mechanical support. Peak VO2 in the LVAD group was 16.0±3.8
ml/kg/min.
Several factors may account for these differences. The EVADE study is a multi-
center study comprising 18 patients. Because it was a multi-center study,
postoperative care, rehabilitation and exercise testing may not have been
identical. Exercise testing was performed earlier after implantation (51.9±20.4
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days), when peak VO2 was not yet optimal (Table 2). Furthermore, the mean
age and weight of our patients were considerably lower than those in EVADE
(37±12 vs. 48±12 years, and 71±8 kg versus 76±12 kg, respectively),
resulting in a higher predicted peak VO2 (39.6 vs. 33.6 ml/min/kg) and a higher
normalized VO2 per kilogram. Most of the aforementioned differences from the
EVADE study also apply to the study of Mancini et al.(7). Furthermore, in that
study, exercise testing was by way of a bicycle ergometer instead of a treadmill,
as used in our study, which may render 10% to25% lower values of peak VO2
(18). However, several small-scale studies in which exercise performance was
measured by way of a treadmill demonstrated  much lower peak VO2  values
(12-17 ml/kg/min) than those found in our study (8-10). Despite these
differences in study design and patient characteristics, we believe that part of
the excellent exercise performance of our patients with a LVAD is due to the
intensive post-implantation training program.
Effect of training in heart failure. The influence of training on exercise capacity
may be inferred from evidence showing that impaired exercise performance in
patients with chronic heart failure is related not only to an impaired
hemodynamic condition, but also to skeletal muscle abnormalities (19-21) like
atrophy (22), as well as alterations in muscle histology and biochemistry (23).
Sullivan et al. demonstrated, for the first time, that training could improve
exercise capacity in patients with severe heart failure (24). Later, many other
studies confirmed this, as reviewed by Piepoli et al. (25). Several studies using
muscle biopsies or nuclear magnetic resonance spectroscopy confirmed the
improvement in muscle metabolism after training, independent of central
hemodynamic changes (26-29). These data demonstrate that in patients with
chronic heart failure, despite a limited cardiac output response, an intensive
training program can improve exercise capacity significantly.
After HeartMate implantation, total cardiac output will increase significantly,
but pump flow is limited to approximately 10 liters/min. At rest, there is usually
no contribution of the native heart; however, during exercise opening of the
aortic valve has been observed, contributing to increased total blood flow.
Based on a flow of 10 liters/min, a male patient should be able to reach a peak
VO2 of approximately 1400 ml/min, if he has a normal hemoglobin and oxygen
extraction. Because this value is similar to that found in our study, we assume
that exercise performance was optimal for the given blood flow. From the onset
of our LVAD program, our policy was aimed at the reversal of skeletal muscle
abnormalities by implementation of an intensive training program guided by a
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physical therapist. The combination of an increase in cardiac output due to
LVAD implantation and intensive post-implantation training likely resulted in
optimal exercise capacity.
Study limitations. Due to an inherent, considerable mortality and morbidity
during the course of LVAD implantation and after successive HTx, only a
limited number of patients was available for a complete longitudinal study of
exercise performance (n=9, Group C). Therefore, additional analyses were
performed on the larger data sets of patients at different time points after LVAD
implantation (Group A, n=10) and one year after HTx with and without a
previous LVAD (Group D, n=10 and n=20, respectively). The relatively young
age of the patients with a LVAD limits the value of direct comparison of VO2
values with those of  post-HTx patients without previous LVAD implantation.
This can be partly overcome by using a percentage of individually predicted
values. Furthermore, as in all small studies, an insignificant difference between
two groups will have limited power. The patients in this study were relatively
young, very motivated and male, which may have skewed the results and
limited generalization to the whole population of patients with end-stage heart
failure.
Conclusion. This study demonstrates that exercise performance in patients with
severe heart failure treated with a TCI HeartMate LVAD, combined with an
intensive rehabilitation program, increases over time and, at 12 weeks, is fully
compatible with activities of normal daily life. Twelve weeks after implantation,
exercise capacity is comparable to that at three months and one year after HTx.
One year after HTx, there appears to be no difference in exercise performance
between patients with and those without a previous LVAD as a bridge to
transplantation. Therefore, with regard to exercise performance, a permanent
LVAD holds promise as a potential alternative for HTx.
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Appendix
During the first two weeks after implantation of the HeartMate, the aim of
training is to get the patient accustomed to exercise. Thereafter, an interval
training program is started, with regular adjustment of the duration and
intensity of the workout. Initially, the training regimen consists of  2-6 min of
low-level activities, alternated with 1-2 min of rest. Training includes sessions
on the bicycle and treadmill, as well as the rowing machine. Coordination is
improved by several games, like badminton, tennis and volleyball. Intensity is
adjusted according to the level of perceived exertion (2-4 corresponding to
“light” to “somewhat hard”) on the Borg scale of  0 to 10, with exertional
dyspnea not exceeding 2 on a dyspnea scale of 0 to 4. Duration of exercise is
gradually increased to 20-40 minutes/day three to five times a week. In
addition, strength and endurance training of local muscle groups, according to
the 5BX plan of the Royal Canadian Air Force (30) is performed.
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Abstract
OBJECTIVES – We sought to evaluate the contractile proteins in
cardiomyocytes of patients with end-stage heart failure (HF) before and after
mechanical support with a left ventricular assist device (LVAD).
BACKGROUND - Improvement of myocyte dysfunction has been suggested
after LVAD support.
METHODS - Fourteen patients’ myocardial biopsies taken at the time of LVAD
implantation and after explantation, at the time of heart transplantation, were
processed for routine hematoxylin-eosin staining and immunohistochemistry
using monoclonal antibodies against actin, myosin, tropomyosin, troponin C
and T and titin. A grading scale from 1 (abnormal staining of all myocytes, no
cross-striation) to 5 (normal fiber anatomy and striation) was used. The cross-
sectional area of cardiomyocytes was also measured.
RESULTS- The cardiomyocytes’ cross-sectional area decreased after support,
from 519±94 µm2 to 319±53 µm2 (p<0.001). Actin, tropomyosin, troponin C,
troponin T and titin at the time of LVAD implantation showed widespread
distortion of architecture; their grades were: 1.4±0.6, 2.3±1.0, 2.1±0.9,
2.1±1.2, 2.0±0.6, respectively. In contrast, myosin morphology was preserved
(4.6±0.7). After LVAD support ,actin, tropomyosin, troponin C, troponin T and
titin showed improvement (grades 2.7±1.3 [p=0.004], 3.2±1.2 [p=0.021],
3.3±0.9 [p=0.004], 3.0±1.1 [p=0.048] and 3.1±0.9 [p=0.001],
respectively),  but no normalization. The myosin pattern deteriorated slightly
(3.6±1.6 [p=0.058]).
CONCLUSIONS – After LVAD support, during a period of 213±135 days in
patients with end-stage HF, despite a decrease in the size of the
cardiomyocytes, severe structural myocyte damage persisted. This does not
support complete recovery of myocyte histologic features.
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Introduction
Heart failure (HF) is a growing problem in cardiovascular medicine. Aging of
the population, prevention of premature death by improved medical and
surgical management as well as better therapy available for the treatment of
chronic HF, results in an increasing number of patients with this syndrome.
Heart failure may be considered a progressive disorder, initiated after an index
event that results in a decline in pumping capacity of the heart. It is
accompanied by activation of neurohormonal and cytokine systems, as well as
adaptive changes in the myocardium called “remodeling” (1). This process of
remodeling includes alterations in left ventricular (LV) geometry, alterations in
extracellular matrix and alterations in the cardiomyocytes’ size, function and
number. Some of the changes reported in failing human cardiac myocytes are
loss of myofilaments and alterations in cytoskeletal proteins(2). One canine
study suggests reversibility of myocyte dysfunction, associated with an increase
in the number of contractile elements, after treatment with beta-blockade (3).
Also, in humans, reversibility of myocyte dysfunction has been suggested after
mechanical support with a left ventricular assist device (LVAD) (4-8). This raises
the option to use LVAD support as a bridge to recovery of cardiac function in
patients with end-stage HF (9-11). The number of patients who have been
weaned from the LVAD, however, is limited, and long-term results are not
available. Unloading the heart with an LVAD will lead to a decrease in cardiac
dimensions and neurohormonal activation (5,12,13). Whether this results in a
significant and sustained reversal of myocyte dysfunction, however, is
questionable (14,15).  Few histologic studies on this subject are available (4-
6,16,17). No microscopic studies of the contractile proteins in myocytes have
been performed. The aim of this study was to evaluate the contractile proteins
in cardiomyocytes by means of routine staining and immunohistochemical
analysis of myocardial biopsies taken at the time of LVAD implantation and to
compare these with biopsies taken at the time of heart transplantation (HTx).
Furthermore the cardiomyocytes’ cross-sectional area before and after LVAD
support was compared.
Methods
Patient group
Fourteen consecutive patients (2 women and 12 men) with refractory end-stage
HF treated with a pneumatic LVAD ( Heartmate, Thoratec, Pleasanton,
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California) as a bridge to transplantation were included in this study (Table 1).
Eight patients had dilated cardiomyopathy (DCM) and six had ischemic heart
disease (IHD).Thirteen patients were successfully transplanted. One patient
died of a recurrent cerebral embolism. The mean duration of LV unloading was
213±135 days (range 71-455 days). Before HTx, all patients were in New York
Heart Association functional class I and demonstrated a very good exercise
performance, as reported previously (18). All cardiac medication had been
stopped. Written, informed consent was obtained from all patients.
Table 1. Characteristics of patients with an implanted LVAD
Male (n) 12
Female (n) 2
Age (years) 32±12
Duration of HF* (months) 5.6±6.1
DCM / IHD (n) 8 / 6
LVEF (%) 13±5
CO (l/min) 3.4±1.2
MAP (mmHg) 64±13
IABP/other support  (n) 7
Duration of LVAD support (days) 213±135
* Time between onset of heart failure symptoms and implantation of LVAD (months).
Immunohistochemical analysis
Myocardial biopsy at LVAD implantation consisted of the LV apical core
removed during Heartmate implantation. These biopsies were compared with
LV tissue specimens of the explanted heart after HTx, from the apical half of the
LV, outside the suture area of the inflow canula. In the one patient who died
before transplantation, tissue specimen of the heart at autopsy were used. All
biopsies were directly fixed in buffered formalin, embedded in paraffin and
routinely processed for hematoxylin-eosin staining on 5-µm sections. Standard
immuno-histochemical analysis was performed using a three-step avidin- biotin
peroxidase reaction. In brief, the sections were deparaffinized and  rehydrated,
and endogenous peroxidase was blocked using a solution of methanol and
hydrogen peroxide. Primary antibodies were applied to the sections for 1 hr
and subsequently demonstrated using a biotinylated horse immunoglobulin G
(IgG) anti-mouse IgG and horseradish peroxidase-labeled streptavidin.
Immunovisualization was performed using 3,3 diamino benzidine tetra
hydrochloride reagents and counterstaining with Mayer’s hematoxylin. The
sections were dehydrated, cleared and embedded in Pertex mounting medium
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(Histolab, Göteborg, Sweden). Primary monoclonal antibodies used in this
study were anti-sarcomere actin (Sigma, Zwijndrecht, the Netherlands), myosin
slow (Sigma), tropomyosin (Sigma), troponin T (Sigma), troponin C (Novocastra)
and titin (Novocastra, Newcastle upon Tyne, United Kingdom). Antigen
retrieval, by boiling sections in a citrate-buffered solution for 15 min, was
performed on the sections for all antibodies except myosin. Sections for myosin
incubation were proteolytic-digested with pepsin for 15 min.
All slides contained large transmural biopsies  and were examined completely
by two to four investigators who aimed for consensus. In these biopsies, all
longitudinal arranged cardiomyocytes were analyzed. In the case of IHD, only
surviving myocytes were studied; the necrotic area was not taken into
consideration. Besides providing a description of the histological findings, a
grading system was also used for the immunohistochemical data, according to
the following scale:
1. Almost all myocytes show a distorted architecture with absence of cross-
striation
2. Some normal myocytes with cross-striation are present; most of the
myocytes are abnormal, however
3. There are normal myocytes with cross-striation, along with myocytes
without cross-striation, or myocytes without antigen staining over the full
length of the contractile fiber
4. There are some myocytes with a distorted architecture; most of the
myocytes are normal, however
5. Almost all myocytes show a normal architecture and cross-striation
To test for inter- and intra-observer variabilities, grading was repeated in half of
the biopsies in a blinded manner, and the kappa value of reliability was
determined. The cardiomyocytes’ cross-sectional area was measured on 3 µm
slides stained with modified azan, making use of a Videoplan morphometric
program (Zeiss Kontron, Eching, Germany). Thirty cells were measured
perpendicular to the long axis; oblique sections were excluded.
Control tissue
Before starting this study in patients with a LVAD, we optimized our technique
of tissue handling and immunohistochemistry on all kinds of human
myocardial biopsies. This was mostly done to rule out the effects of globally
warm ischemia on the biopsies. As normal human LV myocardial tissue is not
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available, atrial auricles obtained at open heart surgery from patients without
HF were used for comparison.
Statistical analysis
Grading of the immunhistochemical data was compared by using the paired
Student-t test. Inter- and intra-observer variabilities were tested using kappa
analysis. A comparison between DCM and IHD was made by using the
unpaired Student-t test. All data were calculated with SPSS version 8.0 for
windows. A p value< 0.05 was considered significant.
Results
Hematoxylin-eosin staining.
At the time of LVAD implantation, all myocardial biopsies showed widespread
hypertrophy of the myocytes, striking vacuolization and absence of normal
cross-striation. Increased amounts of lipofuscin and interstitial fibrosis were
seen (Fig 1a). After LVAD support, at the time of HTx, the biopsies showed less
hypertrophy and vacuolization and some improvement in cross-striation (Fig
1b). None of the patients, however, showed complete normalization. Interstitial
fibrosis appeared to increase in most patients.
Figure 1: Hematoxylin-eosin staining in left ventricular biopsies (original magnification
x50)  before and after LVAD support. (A) Before LVAD support, there were
hypertrophic myocytes with varying nucleair sizes, with vacuolization and interstitial
fibrosis. (B)  After LVAD support, the myocytes showed less hypertrophy and
vacuolization, together with a decrease in myocyte size and an increase in interstitial
fibrosis.
To rule out the effect of the implantation of the inflow cannula on this fibrosis,
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we also examined longitudinal sections of the complete LV. These biopsies
showed that the interstitial fibrosis was diffusely present throughout the whole
LV. The inflow cannula only caused a small local ring of dense fibrous tissue
directly around it. The widespread variation in myocyte histologic features in
both series of biopsies was remarkable, both at LVAD implantation and HTx.
Areas with almost normal structure were neighbored by areas showing severe
morphological disorganization.
Actin
The myocardial biopsies at the time of LVAD implantation showed severe
distortion of actin-staining pattern in nearly all myocytes, with barely any cross-
striation visible (Fig 2a). Within some vacuoles, granular material staining for
actin was discerned.
At the time of HTx, some improvement in actin pattern was observed, with
partly restoration of cross-striation (Fig 2b). Large areas, however, still
demonstrated an abnormal architecture.
Myosin
Remarkably, biopsies taken at the time of LVAD implantation showed an
almost normal myosin architecture (Fig 2c). In the vacuoles, no myosin-positive
material was discerned. In contrast to the partial improvement in actin staining,
myosin staining demonstrated a slight deterioration at the time of HTx (Fig 2d).
Tropomyosin, roponin C and T and Titin
The staining pattern for these antibodies was comparable to that of actin
staining, but less pronounced. At the time of LVAD implantation, some cross-
striation was seen, but there were also large areas with disorganization and a
lack of contractile material. Within individual cardiomyocytes, a wide
variability of the staining pattern was occasionally observed. At the time of
HTx, biopsies showed some improvement of cross-striation, but areas with
disorganization persisted. Within each cardiomyocyte, the staining pattern
appeared to be more homogeneous after LVAD support than before it. Between
cardiomyocytes, however, the variability in the staining pattern increased. This
frequently resulted in alternation of structurally normal myocytes with
apparently abnormal myocytes in the same contractile fiber - a peculiar
phenomenon not mentioned before in the published data (Fig 3).
The titin-staining pattern was comparable to that of the other thin contractile
filaments.
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Figure 2: A: Actin staining before LVAD support shows a severe distortion of the
architecture and absence of cross-striation in nearly all myocytes (grade 1). B: Actin
after LVAD support demonstrates some improvement in the staining pattern, with
partial restoration of cross-striation (grade 3). C: Myosin before LAVD support displays a
normal architecture (grade 5). D: After LVAD support, some deterioration is observed
(grade 3). (original magnification x250).
Grading of the contractile proteins
A clear pattern can be delineated (Table 2, Figure 4); the thin, contractile
filaments and titin demonstrated widespread disorganization at the time of
LVAD implantation and showed improvement after support (p=0.004 for actin
pre-vs. post-support). In contrast, myosin, the main constituent of the thick
contractile filament, displayed an almost normal morphology, demonstrating a
slight deterioration after LVAD support ,although not significant (p=0.058).
The inter- and intra-observer kappa values were 0.55 and 0.63, respectively,
indicating fair agreement. Ischemic heart disease showed a worse staining
pattern of the thin contractile filaments at the time of LVAD implantation than
DCM (p<0.05 for actin, troponin C and titin). After LVAD support, this
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difference disappeared.
Figure 3: Tropomyosin staining after LVAD support show the alternation of
histochemical normal myocytes with  abnormal ones in the same contractile fiber
(original magnification x150).
There was no correlation between the grading of the contractile elements in
individual patients and the duration of HF symptoms, the duration of LVAD
support, the dose and duration of catecholamine support before LVAD
implantation or the use of an intra-aortic balloon pump before support.
Cross-sectional area of the cardiomyocytes
The cardiomyocytes’ cross-sectional area decreased significantly, from 519±94
µm2 before LVAD support to 319±53 µm2 after support (p<0.001), a reduction
of 36±19%. Normal values in five control-patients showed a cross-sectional
area of 226±67 µm2.
Normal atrial auricle tissue
The atrial cardiomyocytes of patients undergoing coronary artery bypass graft
surgery  showed a normal staining pattern of the contractile proteins (Fig. 5).
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Table 2. Grading scale of the contractile proteins
LVAD implantation Heart transplantation
Actin
DCM 1.6±0.7 2.6±1.4
Ischemic 1.0±0.0* 2.8±1.3
All 1.4±0.6 2.7±1.3 (p=0.004)
Myosin
DCM 4.8±0.5 3.4±1.6
Ischemic 4.3±0.8 3.8±1.6
All 4.6±0.7 3.6±1.6 (p=0.058)
Tropomyosin
DCM 2.6±0.9 3.3±1.3
Ischemic 1.8±1.0 3.2±1.2
All 2.3±1.0 3.2±1.2 (p=0.021)
Troponin C
DCM 2.5±0.8 3.0±0.9
Ischemic 1.5±0.8* 3.7±0.8
All 2.1±0.9 3.3±0.9 (p=0.004)
Troponin T
DCM 2.0±0.9 2.6±1.2
Ischemic 2.2±1.6 3.5±0.8
All 2.1±1.2 3.0±1.1 (p=0.048)
Titin
DCM 2.3±0.5 3.3±1.0
Ischemic 1.7±0.5* 3.0±0.6
All 2.0±0.6 3.1±0.9 (p=0.001)
Data are presented as the mean value ± SD. * p< 0.05 for IHD versus DCM, at the
time of LVAD implantation.
Discussion
In the present study, for the first time, to the best of our knowledge,
immunohistochemical data on contractile proteins in cardiomyocytes are
reported in patients with end-stage HF treated with an LVAD. This study
showed that the myosin structure was preserved in patients with end-stage HF
before LVAD implantation. In contrast, the thin, contractile filaments and titin
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demonstrated widespread distortion of the normal staining pattern, with actin
displaying the worst degradation. After LVAD support, a partial improvement in
morphology of the thin contractile filaments and titin had occurred. In contrast,
myosin demonstrated a slight  deterioration in histologic features. Furthermore,
after LVAD support, the staining pattern within each cardiomyocyte appeared
to be more homogeneous. Between different cardiomyocytes, however, the
variability in the staining pattern persisted, leading sometimes to the alternation
of apparently abnormal myocytes with normal ones in the same contractile
fiber. This may affect cardiac contractility in a negative way and may also affect
the spread of the electrical impulse, creating a condition for re-entry.
Finally, a significant decrease in the cardiomyocytes’ cross-sectional area after
LVAD support was demonstrated, although normalization was not complete.
Figure 4: Grading of the contractile proteins in myocytes before and after LVAD
support. Myosin staining showed some deterioration (grade 4.6 before LVAD
implantation vs. 3.6 after LVAD support; p=0.058). In contrast, the contractile proteins
of the thin filaments and titin showed improvement (grade 1.4 for actin before LVAD
implantation vs. 2.7 after LVAD support; p=0.004). Severe structural myocyte damage
persisted, despite a period of LVAD support of 213±135 days.
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The role of immunohistochemistry in HF
Immunohistochemic studies on myocardial tissue in chronic HF are scarce and
comprise mainly hearts with DCM (2,19,20). With respect to the thin
contractile filaments and titin, our results correspond to these studies. In
contrast to the study reported by Hein et al. (19) the myosin pattern in our
patients with end-stage HF was remarkably preserved. This relative sparing of
myosin, however, has been demonstrated before in a study of dogs in whom
regional ischemia was induced by ligation of the left anterior descending
coronary artery (21).
Figure 5: Human atrial cardiomyocytes show normal cross-striation (actin staining,
grade 5; original magnification x250).
Recovery of myocyte function
Despite persistence of widespread areas with a distorted myocyte architecture,
as shown in this study, LVAD implantation leads to an impressive improvement
in the hemodynamic condition in our patients (18), as well as in those reported
in other studies. The decrease in cardiomyocyte size is in accordance with
other studies (17,22, 23). Furthermore, LVAD support results in a decrease in
cardiac dimensions (4-6,17,24), an improvement of myocyte-(7,25,26) and
mitochondrial function (27, 28), an improvement of neurohormonal activation
(12,13,17), an increase in beta- receptor density (29) and disappearance of
antibodies against beta- receptors (9) as well as a decrease in serum interleukin
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(IL)-6 and IL-8 (30). Recently, a decreased susceptibility to apoptosis (31) and a
reduction in tumor necrosis factor-alpha activity in nonischemic
cardiomyocytes after support were shown (32). Histologic studies after LVAD
support showed a reduction of wavy fibers, contraction band necrosis and
myocytolysis, accompanied by an increase in myocardial fibrosis (4-
6,8,9,16,17), although recently, a reduction in the collagen content was also
reported after LVAD support (23).
These alterations, however, probably resulted from unloading of the heart with
consequent circulatory recovery and may not be specific for LVAD support at
all. Medical therapy (e.g. angiotensin-converting enzyme inhibitors and beta-
adrenergic blockers) also improves the circulatory status and slows
deterioration of the failing heart, a benefit that is partly due to inhibition of
remodeling (14, 33). Furthermore, spontaneous improvement in LV function is
well known in myocarditis and in peripartum cardiomyopathy and was also
reported in 27 % of patients with recent-onset DCM (34). This may partly
explain the number of patients being weaned from LVAD support in some
studies. It is evident that in these situations, an LVAD can play an important
role in keeping a patient alive and gaining time for cardiac improvement. At
present, however, there is no evidence available that LVAD support can be a
permanent cure for patients with HF (15). The extent of myocardial recovery
after LVAD support is highly variable (11,35,36), and there are conflicting data
on the amount of fibrosis after support. The increased fibrosis demonstrated in
our study and by others (4,6,37), will have a negative impact on systolic and
diastolic cardiac function, limiting the chance for complete recovery.
Furthermore, the inadequate presence of titin after LVAD support, as seen in
our study, can hamper the formation of new sarcomeres, because titin is
necessary as a template for the organization of newly synthesized myosin and
actin filaments (19).
A new and intriguing strategy that combines mechanical and intensive
pharmacological therapy to promote reverse remodeling and uses clenbuterol
to induce physiologic hypertrophy has been suggested -  the Harefield
approach (38, 39). This requires further studies to determine the long-term
efficacy and to elucidate the concepts of reverse remodeling (39).
Study limitations
In principle, abnormalities observed in cardiac biopsies could partly be caused
by global warm ischemia of cardiac tissue after obtaining the biopsies.
Diseased human hearts are extremely susceptible to the effects of ischemia,
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particularly the contractile proteins (20). Therefore, we optimized our tissue
handling so that 90 % of the biopsies were fixed within 10 minutes. The
normal architecture of the myosin pattern in the patients with HF argues against
global ischemia as a potential mechanism for our findings, because in the study
of Hein et al.(20), it was shown that all contractile proteins are equally sensitive
to the effect of global ischemia. Furthermore, our control biopsies were also
exposed to the potential effect of global ischemia, but showed a normal
staining pattern of the contractile proteins. Most importantly, in this study,
every patient is its own control. The improvement in the staining pattern of all
thin contractile proteins and titin in the biopsies after LVAD support, which are
handled in the same way as before LVAD placement, is a strong argument
against the effects of global warm ischemia.
Another problem is that biopsies may not be representative of the whole heart.
This problem is overcome, in the greater part in this study, by the quantity of
available tissue (1-3 cm. biopsies).
All our patients had end-stage HF. It cannot be ruled out that patients with less
severe forms of HF may actually show more recovery of myocyte histologic
features after LVAD support.
The rather long duration of LVAD support in this study may mean that the
optimal period of recovery has been exceeded, because some clinical and
animal studies suggest that recovery is complete within a couple of weeks (11,
26, 40).
In our patients with LVAD support, all cardiac medications were stopped. It is
not known to what extent this could have influenced recovery; this will be an
area for future research.
Conclusion
Despite impressive hemodynamic recovery, a decrease in the cardiomyocytes’
cross-sectional area and an improvement in staining pattern of the thin
contractile elements and titin, our findings endorse the persistence of severe
structural myocyte damage after a long duration of LVAD support (213±135
days). Our findings do not support complete recovery of myocyte histologic
features after a period of unloading of the heart by  LVAD support.
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Abstract
BACKGROUND- Left ventricular assist device (LVAD) implantation in patients
with end-stage heart failure results in impressive hemodynamic improvement.
The effects on myocardial apoptosis and its mediators are unknown.
METHODS- Myocardial biopsies from 17 patients at the time of LVAD
implantation and after explantation, at the time of heart transplantation (HTx)
were examined by TUNEL reaction and with antibodies against Fas Ligand
(FasL), Fas, TNFα receptor 1 (TNFR1), TNFα receptor 2 (TNFR2), TNFα, TNFα
converting enzyme (TACE), Poly (ADP-ribose) polymerase (PARP), Poly ADP-
ribose (PAR), Caspase 3 and FLICE inhibitory protein (FLIP).
RESULTS- Apoptosis incidence was low: 0.8 % of cardiomyocytes (range 0-3)
before support, and 0.1 % (range 0-0.6) positive cardiomyocyte nuclei after
support (p< 0.01). This was accompanied by low expression of caspase 3 and
high expression of the DNA repair enzyme PARP.  Its product PAR increased
after support. Mediators and receptors inducing apoptosis, and FLIP were
widely present before and after support.
CONCLUSION- Despite the abundant presence of mediators and receptors
inducing apoptosis, the incidence of apoptosis itself was low before and after
mechanical support. The abundant expression of FLIP may suggest an
important role for this protein in the inhibition of cardiomyocyte death.
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Introduction
Heart failure is a progressive disorder accompanied by activation of
neurohormonal and cytokine systems and adaptive changes in the myocardium
called remodeling.1 Myocytes and fibroblasts are the major cardiac cells
involved in this remodeling process. Ongoing myocyte cell death is thought to
be one of the mechanisms leading to progressive ventricular dysfunction.2
There is accumulating evidence that this cell death occurs partly through
apoptosis, although it is not yet known to what extent.3 Different degrees of
apoptosis have been documented in end-stage heart failure.4-6 Only few studies
have dealt with the occurrence of apoptosis in patients with end-stage heart
failure treated with a left ventricular assist device (LVAD).7,8 No systematic
study has been performed on apoptosis mediators and receptors in patients
with end-stage heart failure treated with a LVAD.
The aims of this study were, firstly, to evaluate the apoptotic process and its
related mediators in patients with acutely deteriorating end-stage heart failure,
and secondly, to investigate the effect of LVAD support on these processes. For
this study we performed immunohistochemical analysis of myocardial biopsies
taken at the time of LVAD implantation and compared these with biopsies
taken at the time of heart transplantation (HTx).
Methods
Patient population
This study included 17 patients (15 males, 2 females; mean age 34±13 years,
range 18-53) with refractory end-stage heart failure treated with a LVAD
(HeartMate, Thoratec, Pleasanton, California) as a bridge to transplantation. Ten
patients had dilated cardiomyopathy (DCM) and 7 ischemic heart disease
(IHD). All patients were in NYHA class IV and on intravenous inotropic
medication. Seven patients were also treated with an intra-aortic balloon pump.
Mean LV ejection fraction was 15±5 %. Mean cardiac output was 3.7±1.4
L/min; mean arterial pressure 64±12 mm Hg. All patients were successfully
transplanted after a mean duration of left ventricular support of 211±115 days
(range 71-455). While on the LVAD all patients were in NYHA functional class
I and had a very good exercise performance.9 All cardiac medication had been
stopped, except for low dose aspirin. Written informed consent was obtained
from all patients.
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Immunohistochemical analysis
Myocardial biopsy at LVAD implantation consisted of the left ventricular apical
core removed during HeartMate implantation. These biopsies were compared
to large left ventricular free wall tissue specimen of the explanted heart after
HTx. All slides contained large transmural biopsies and were examined
completely by three investigators. All biopsies were directly fixed in buffered
formalin and embedded in paraffin. Primary antibodies were used against Fas
ligand (FasL), Fas, TNFα- receptor 1 and 2 (TNFR1, TNFR2) (all Sanvertech,
Santa Cruz, California USA), TNFα (Hycult Biotechnology, Uden, the
Netherlands), TNFα-converting enzyme (TACE, a gift from Immunex
Corporation, Seattle, USA), Poly-ADP-ribose polymerase (PARP, Sanvertech),
Poly-ADP-ribose (PAR, Kordia Life Sciences, Leiden, the Netherlands), Caspase
3 (CCP32, Dakopatts, Denmark) and FLICE Inhibitory Protein (FLIP long and
short, Sanvertech).
Detection of these primary antibodies was performed using either a
combination of  horseradish peroxidase (HRP) labelled second and third
antibodies, or using biotinylated second antibody with HRP labelled
streptavidin. HRP of all immuno reactions was visualised using
diaminobenzidine (DAB) development with H2O2 as substrate. After
counterstaining with Mayer’s Haematoxilin, sections were dehydrated  in
ethanol, cleared in xylol and embedded in Pertex mounting medium (Histolab,
Göteborg, Sweden).
For FLIP (L + S) visualisation, all incubations were performed on aceton fixed
frozen sections, sections were incubated overnight at 4 0C using an isotype
mouse IgG1 as control. The demonstration of FLIP was performed using
Powervison system (Klinipath, the Netherlands).
Apoptosis was demonstrated using terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labelling (TUNEL) according to the method of
Wijsman et al.10 As positive control biopsies we used cardiac samples of heart-
transplant patients with severe acute rejection, as discussed previously.11
Quantitative FLIP mRNA expression
RNA was isolated using TRIzolTM Reagent (GibcoBRL, Rockville, USA). Three
µg of RNA was used for cDNA synthesis using oligoDT and random primers.
Primers and probes were designed for use at the ABI Prism 7700 sequence
Detection System (Applied Biosystems, New Jersey, USA). FLIP L/S  forward
and reverse primers: 5’-CCA-CTG-GAA-AGG-ATT-CTG-AAA-GAA-3’ and 5’-
AAG-CTC-ACA-AGG-GTC-TTG-CAG-TA-3’, FLIP L/S probe: 5’-FAM-CAG-CTC-
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CGG-GCC-AGT-CAA-CAG-AA-TAMRA-3’ (Biosource, Foster City, USA).
Porphobilinogen deaminase (PBGD) was chosen as a reference gene, using
PBGD forward and reverse primers: 5’-GGC-AAT-GCG-GCT-GCA-A-3’ and 5’-
GGG-TAC-CCA-CGC-GAA-TCA-C-3’, PBGD probe: 5’-VIC-CAT-CTT-TGG-
GCT-GTT-TTC-TTC-CGC-C-TAMRA-3’ (Applied Biosystems).
For quantitative RT-PCR, the TaqmanTM-PCR core reagent kit was used (Applied
Biosystems). PCR reactions were carried out in a final volume of 50 µl
containing: 1x TaqmanTM buffer (final concentration), 40 mmol dNTP’s and
1.25 Units Ampltitaq Gold. In case of  FLIP 2.5 pmol of both primers, 7.5 pmol
probe and 150 mmol MgCl2 were added. The reaction mixture for PBGD
contained 15 pmol of both primers, 10 pmol probe and 250 mmol MgCl2. The
following thermocycle profile was used: 95 °C for 10 min followed by 40
cycles of 95 °C for 15 sec and 60 °C for 1 min. Each sample was run in duplo.
The following formula was used to quantify our samples: relative quantity = 2 -
∆∆Ct, ∆∆Ct = ∆Ct (sample) - ∆Ct (calibrator) and ∆Ct = Ct (target) – Ct
(reference). The calibrator sample, cDNA of  PHA stimulated blood
mononuclear cells of a healthy volunteer,  was run each time and therefore, it
was possible to make an interrun comparison. For normal comparison FLIP m-
RNA was also quantified in 7 myocardial biopsies peroperatively taken from
donor hearts and from patients undergoing coronary bypass operation.
Statistical analysis
Results are given as mean ± SD. Student’s paired or unpaired t test was used
for statistical comparison, as appropriate. All data were calculated with SPSS
8.0 for windows. A p value< 0.05 was considered significant.
Results
Apoptosis
The number of TUNEL positive nuclei was counted per 150 cardiomyocyte
nuclei at magnification 400 x and expressed as percentage. Only dark brown
stained nuclei were counted as positive; ambiguously stained nuclei, which
were especially present in the biopsies before LVAD implantation, were scored
negative.
A low incidence of TUNEL positive myocytes was seen both at the time of
LVAD implantation and after support, at the time of HTx. In 15 patients this
was 0.8% (range 0-3%)  of cardiomyocyte nuclei positive before, and 0.1%
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(range 0-0.6 %) after LVAD support (p<0.01) (Table 1).
Table 1  Histochemical data of apoptosis before and after LVAD support
TUNEL Caspase-3 PARP PAR
before LVAD 0.8 %
(0-3 %)
weakly present 3.6±0.6 1.0±0.0
after LVAD 0.2±0.4*
(0-0.6 %)
weakly present 3.2±0.9 1.6±0.8†
*= p< 0.01; †= p< 0.007
TUNEL: percentage of positive staining nuclei (range).PARP: Poly (ADP-ribose)
polymerase; PAR: Poly ADP-ribose; grade1= 0-25% of myocytes positive; 2= 25-50%
of myocytes positive; 3= 50-75% of myocytes positive; 4= 75-100% of myocytes
positive.
Figure 1. In this figure an example of high incidence TUNEL positivity is shown (A).
This TUNEL positivity did not correlate with high caspase-3 activity (B) suggesting that
the TUNEL staining in this patient was not indicative of apoptosis. (original
magnification 100 x).
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In two patients a remarkably high incidence of TUNEL positivity was observed
before LVAD implantation: 26 % and 97 % positive cardiomyocyte nuclei,
respectively (fig 1a). In these two patients TUNEL reaction was repeated on
frozen sections, lacking the proteolytic digestion with pepsin which is required
for the TUNEL reaction on paraffin.11 These two slides showed complete
absence of TUNEL positive cardiomyocyte nuclei, suggesting that the TUNEL
positivity on the paraffin slides was not indicative of apoptosis. No frozen tissue
was available of all patients, however. After LVAD support the incidence in
these two patients decreased to low numbers, in accordance with the other
patients.
Figure 2. This shows the normal situation of positive TUNEL staining in endothelial
cells (endocard) (A) corresponding with caspase 3 activity (arrowheads) (B). (original
magnification 100 x).
In all patients a higher incidence of TUNEL positivity was seen in infiltrating
cells, endothelial and endocardial cells (fig 2a) and in fibrous tissue
surrounding infarcted areas. In general, the subendocardial area showed more
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TUNEL positive cardiomyocytes than the deeper layers. Regarding
cardiomyocyte apoptosis, hearts of patients with DCM showed lower numbers
than hearts of patients with IHD. Especially patients with recent infarctions
showed higher numbers of apoptotic cardiomyocytes. The number of TUNEL
positive myocytes related neither with the dose and duration of inotropic
support nor with the hemodynamic data before LVAD implantation in this
patient group.
Caspase 3
Most myocytes showed a weak cytoplasmic staining of caspase 3 (Table1).
However, nuclear expression was scarce. After LVAD support the picture was
similar. Endothelial and endocardial cell nuclei were often positive before and
after LVAD support (fig 2b). There was no difference between IHD and DCM.
TUNEL positive nuclei were often caspase 3 positive. In the two patients that
showed a very high percentage of TUNEL positivity, nuclear expression of
caspase 3 was much lower (fig 1b), suggesting that the TUNEL staining in these
patients was not indicative of apoptosis, as was also suggested by the TUNEL
reaction on frozen sections.
Poly (ADP-ribose) polymerase (PARP)
This DNA repair enzyme was widely present in the nuclei of cardiomyocytes
before and after LVAD support (fig 3a). We quantified the activity by using the
following grading: 1= 0-25% of myocytes positive; 2= 25-50%; 3= 50-75%;
4= 75-100%. For the whole group the grading decreased from 3.6±0.6 to
3.2±0.9 (p< 0.05) (Table 1).
There was no difference between DCM and IHD patients.
Poly ADP-ribose (PAR)
In contrast to PARP expression, the nuclear expression of its product, Poly
ADP-ribose (PAR) was only very weak. We used the same scoring system as
with PARP, resulting in 1.0±0.0 before support and 1.6±0.8 after support (p<
0.007) (Table 1).
FasL
Before and after LVAD support almost all myocytes showed a weak
cytoplasmic staining for FasL in DCM hearts as well in ischemic hearts.
Expression at the cellular membrane was only sporadically observed.
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Figure 3. Regulators of apoptosis in patients with end-stage heart failure, before LVAD
support. A, PARP expression showing almost all cardiomyocyte nuclei positive (original
magnification 50 x); B, Fas staining, demonstrating diffuse weak cytoplasmic expression
(original magnification 50 x); C, Diffuse cytoplasmic  presence of TNF receptor 1, with
some expression on the sarcolemma (arrowheads) (original magnification 150 x); D,
cytoplasmic expression of FLIP (original magnification 100x).
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Fas
Most of the myocytes demonstrated a weak cytoplasmic expression of Fas
activity (fig 3b) and sometimes at the cell surface. After LVAD support there
was no noticeable change in staining pattern. Again, no difference between
DCM and IHD patients was noted. Some intercalated discs showed positive
staining.
TNFα
Both DCM and IHD patients showed positive staining for TNFα in part of the
myocytes. The activity sometimes had a patchy localization with more positive
staining on the endocardial side of the myocardium and in the papillary
muscles and less staining on the epicardial side. After LVAD support most
myocytes still showed TNFα  expression, although it was slightly diminished in
some patients.
TNFα  Converting Enzyme (TACE)
TACE staining before and after support followed that of TNFα in most patients
but, on the whole, demonstrated a slightly weaker expression. Most activity
was detected in the cytoplasm and not , as might have been expected, at the
sarcolemmal site.
TNFα  Receptor 1 (TNFR1)
All myocytes showed cytoplasmic staining for TNFR1 as well as expression at
the cell membrane (fig 3c). After LVAD support  some patients showed no
surface expression anymore, both in the DCM and the IHD group, but in the
majority of  patients expression was unchanged.
TNFα  Receptor 2 (TNFR2)
Before LVAD support almost all DCM patients showed cytoplasmic and
sarcolemmal expression of TNFR2. After support this expression decreased
slightly. In  some patients it was no longer detected. In patients with IHD the
expression of TNFR2 before and after LVAD support appeared to be a little less
pronounced than in the DCM group.
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Figure 4. FLIP m-RNA in normal cardiac tissue and in DCM and IHD patients with end-
stage heart failure. The relative abundance of FLIP m-RNA, measured by quantitative
PCR, is comparable in normal cardiac tissue and in heart failure patients before and
after LVAD support (p= NS).
FLIP
FLIP m-RNA was demonstrated in cardiac tissue, in the same amount before
LVAD implantation as after LVAD support (0.79±0.31 relative units before,
0.65±0.33 after support; p=NS) . It did not differ from the amount in hearts
without heart failure (0.66±0.07, fig 4). Immunohistochemistry confirmed the
presence of FLIP mainly in the cytoplasm of cardiomyocytes (fig 3d). No
difference was observed before and after LVAD support. Isotype controls were
negative.
Discussion
In the present study, comprising a group of relatively young patients with
severe heart failure, a remarkably low incidence of apoptotic cardiomyocytes
was demonstrated (0.8%) together with a low caspase 3 activity. In contrast,
expression of the DNA repair enzyme PARP was quite high. Its product PAR,
on the other hand, was mostly absent, but increased after LVAD support, along
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with a further reduction in TUNEL positive cardiomyocytes. This suggests
decreased apoptosis and increased DNA-repair after LVAD implantation,
probably due to a reduction in myocardial stretch and decreased
neurohormonal activation.
 Apoptosis inducing ligands (TNFα and FasL) were present in most of the
cardiomyocytes and decreased only slightly or not at all  after LVAD support.
TACE expression coincided with that of TNFα, although on a lower level of
activity. Transmembrane receptors belonging to the TNF receptor superfamily
(TNFR1, TNFR2, Fas) were present both in the cytoplasm and on the membrane
of most cardiomyocytes in end stage heart failure, although Fas surface
expression was only week. After LVAD support the expression of TNFR2 in
DCM patients decreased slightly. FLIP was widely distributed in the
cardiomyocytes before and after mechanical support, comparable to the level
in normal hearts.
Apoptosis in heart failure
Progressive loss of cardiomyocytes by apoptosis is thought to be an important
pathogenic mechanism of heart failure.3 Initially, high levels of apoptosis were
reported (5-35%), 5 but in subsequent studies apoptosis rates of less than 1 %
were presented,4,6 corresponding with the results in our study. Maybe end-stage
heart failure represents a “burnt-out” state, characterized by minimal ongoing
apoptosis.3 Some caution has to be taken because of the sometimes localized
nature of the apoptotic process, with a preference for the subendocardial
regions. An additional problem in the determination of the role of apoptosis in
heart failure is the limited specificity of the TUNEL method, because necrotic
cardiomyocytes and postmortem autolysis as well as vital cardiomyocytes
showing DNA repair and RNA synthesis have been reported to lead to TUNEL
positivity as well.12-14 This may be the explanation for the high incidence of
TUNEL positive cardiomyocytes in two patients in this study and in some
previous reports on apoptosis in heart failure. The absence of caspase 3 staining
in these two patients and the absence of TUNEL positivity on frozen sections
made us believe that the extensive positive TUNEL staining on the paraffin
slides in these patients  is not caused by apoptosis. In these patients the
combination of proteolytic pretreatment required on paraffin sections for the
TUNEL reaction and a particular status of nucleus pre-LVAD may have caused
the TUNEL positivity. This may also be the reason for the ambiguously stained
nuclei by the TUNEL reaction in most patients. Also this staining was mainly
observed pre-LVAD.
The low expression of caspase 3 in this study and in others15,16 is in accordance
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with the low incidence of apoptosis because caspase-3 represents the final
common pathway of the caspase cascade resulting in DNA cleavage.17 The
high expression of  the DNA repair enzyme PARP that we found suggests that
the cardiomyocytes were relatively resistant to apoptosis.18 Caspase 3
inactivates PARP early in the apoptotic process,19 but the antibody used in this
study recognizes both the full-length molecule and the 85-kDa cleaved
fragment. Other studies, however, have already shown negative
immunostaining for 24-kDa PARP fragments in end-stage heart failure.15 In
contrast to cardiomyocytes, endothelial and endocardial cells, exhibited
considerable presence of apoptosis as was also reported by others.8 This may
suggest that myocardial apoptosis is promoted by the diffusion of soluble pro-
apoptotic mediators, like TNFα, FasL or free radicals, from the blood or from
endothelial cells.20,21
Apoptosis in patients treated with a LVAD
Only few other studies on apoptosis in LVAD patients are available.7,8,16 In the
study of Bartling et al.7 a decrease of apoptosis after LVAD support was
demonstrated by DNA fragment laddering. In contrast to our study these
authors did not compare TUNEL stained biopsies before and after LVAD
treatment. Therefore, it can not be excluded that the attenuation of DNA
fragmentation after LVAD support may have been the result of a reduction in
apoptotic interstitial cells. These may make a major contribution to the
apoptotic ladder patterns, as is demonstrated for instance in acute rejection
after heart transplantation11 and in transgenic mice with cardiac-specific
overexpression of TNFα.22 The study of Francis et al.8 showed very little
evidence for cardiomyocyte apoptosis in patients with end-stage heart failure,
but found overexpression of Bcl-2 and PCNA (proliferating cell nuclear
antigen). Birks et al.16 demonstrated elevated myocardial caspase-9 expression
in patients with end-stage heart failure at the time of LVAD implantation, but
caspase-3 was not elevated, in accordance with our study. They did not
perform TUNEL reactions in those biopsies, however.
Apoptosis related mediators in heart failure and after LVAD
TNFα is synthesized as a large inactive protein, which is activated by a tissue
metalloproteinase called TNFα converting enzyme (TACE).23 Two types of
TNFα receptors have been identified: a 55-kDa (TNFR1) and a 75-kDa
(TNFR2). Both receptors are expressed on adult human cardiomyocytes.24
Induction of apoptotic cell death by TNFα is predominantly mediated by
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TNFR1.25
TNFα mRNA and protein and TACE have been demonstrated before in
explanted hearts from patients with end-stage heart failure.26,27 After LVAD
support decrease of immunohistochemic TNFα expression in a study with 8
patients has been reported.28 The largest reduction however, was in the 4
patients who could be weaned from the assist device, suggesting that the
reduction of TNFα was not only caused by unloading, but maybe also by the
natural history of the underlying disease. In our study, reduction of TNFα
expression and TACE after LVAD support was only very modest.
Another mechanism for the induction of apoptotic cell death is the cross-linking
of Fas and Fas-L.29 This is an important mechanism in the down-regulation of
immune responses and effector activities, such as in T cell-mediated
cytotoxicity 30 and ischemic myocardial cell death.31 A study in rats, however,
showed no enhanced cardiomyocyte apoptosis despite the presence of FasL
and Fas. 32
It is assumed that FLIP may contribute to the blockade of the death signaling
pathways in cardiomyocytes.31,33 This protein is abundantly present in the heart,
as was also demonstrated in our study. In this way most cardiomyocytes are
protected from apoptotic cell death, in contrast to other cardiac cells, like
endothelial cells. Other inhibitors of apoptosis, like NFκB and  anti-apoptotic
factor A1, a member of Bcl-2 family proteins are also potential regulating
factors of cardiomyocyte cell death in end-stage heart failure, but were not
investigated in this study.
Conclusion
In the conundrum of end-stage heart failure we still do not know if progressive
cardiac dilatation occurs because of  progressive deterioration of myocyte
function, or because of a reduction in myocyte number.34 In the present study,
a low incidence of apoptotic cardiomyocytes was observed, despite  the
abundant presence of apoptosis-inducing mediators and their specific receptors.
To us, this would suggest that deterioration of myocyte function is more
important than the reduction in myocyte number. This is in agreement with our
previous study in which we demonstrated severe structural damage of the
contractile proteins in end-stage heart failure, which did not completely resolve
after LVAD support, 35 while the number of apoptotic cardiomyocytes in this
study decreased significantly after LVAD support. The abundant expression of
FLIP may suggest an important role for this protein in the inhibition of
cardiomyocyte death.
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Abstract
OBJECTIVES-  To evaluate if the morphology of the contractile proteins in
cardiomyocytes of patients with end-stage heart failure, treated with a left
ventricular assist device (LVAD), is identical in the left- and right ventricle (LV,
RV) and in the interventricular septum (IVS) and can be monitored by biopsies
taken with a bioptome.
BACKGROUND-  Application of a LVAD as a bridge to recovery of cardiac
function requires monitoring of myocyte recovery. The use of right ventricular
biopsies for this could be feasible, if morphologic findings in the RV coincide
with those in the LV.
METHODS-  At the time of heart transplantation myocardial biopsies of LV, RV
and IVS from 13 patients after LVAD support were compared using
immunohistochemistry with monoclonal antibodies against the contractile
proteins. Additionally, in 5 patients, small biopsies obtained with a diagnostic
bioptome were compared with large transmural biopsies. Hemodynamic
monitoring was performed when the patients were fully recovered from the
implantation, to rule out persistent RV failure.
RESULTS-  The staining pattern of actin, myosin, tropomyosin, troponin T and
C was identical in the biopsies of LV, RV and IVS. Small biopsies taken with a
bioptome appeared to be representative for the larger biopsies. Hemodynamic
monitoring showed absence of RV failure in our study group.
CONCLUSION- In the absence of RV failure, morphology of the contractile
myofilaments after LVAD support for 215±143 days,  is identical in LV, RV and
IVS, allowing for monitoring of the possible occurrence of LV reverse
remodeling by RV biopsies.
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Introduction
The growing number of heart failure patients and the shortage of donor hearts
warrant exploration of other therapeutic options for patients with end-stage
heart failure. Left ventricular assist devices (LVAD’s) can be used successfully as
a bridge to transplantation (1-4). In selected patients, LVAD’s may even offer an
alternative to transplantation, with  significant survival and quality of life
benefits  one year after implantation, compared to patients treated
pharmacologically (5). This includes a favorable exercise capacity while on the
device, which is comparable with that after heart transplantation (6).
Some reports suggest the use of LVAD’s as a bridge to recovery of cardiac
function in selected patients (7-9), although long-term results are scarce. Others
question the use of a LVAD as a bridge to recovery (10,11). Alternative
treatment protocols, combining mechanical support with intensive
pharmacological therapy, or other modalities such as growth hormone, gene
therapy and myocyte or stem cell transplantation, may hold the key to better
long-term results (12,13). The appropriate monitoring of recovery, however, is a
critical step in all these therapeutic options.
Most studies of reversal of myocyte dysfunction have only dealt with left
ventricular tissue. Recently one study, looking at LV and RV myocyte size,
SERCA 2a content and force-frequency relations of isolated superfused
trabecula, suggested differential left and right ventricular reverse remodeling
after LVAD support. This might suggest that reduction of mechanical load is a
primary factor underlying reverse remodeling (14).
We previously reported the persistence of severe structural damage of the
contractile proteins in left ventricular myocytes after a long duration of LVAD
support, using immunohistochemistry (15). We wondered whether this
technique might be used to monitor recovery in LVAD patients on a
prospective base, by inspecting right ventricular biopsies obtained via the usual
jugular vein approach. Obviously, this would only be feasible if the findings in
the right ventricular biopsies would coincide with those in the left ventricular
biopsies.
Therefore, the aim of this study has been to compare the state of the contractile
myofilaments in cardiomyocytes using immunohistochemical analysis of
myocardial biopsies taken from the left ventricular free wall (LV), the
interventricular septum (IVS) and the right ventricular free wall (RV) after LVAD
support, at the time of heart transplantation (HTx). In addition, small biopsies
taken with a diagnostic bioptome were compared with large transmural
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biopsies.
Methods
Patient population
This study included 13 patients  (12 males, 1 female) with refractory end-stage
heart failure treated with a pneumatic LVAD (HeartMate, Thoratec, Pleasanton,
California) as a bridge to transplantation (Table 1). Six patients had dilated
cardiomyopathy (DCM) and 7 ischemic heart disease (IHD). One patient died
due to recurrent cerebral embolism, the other 12 patients were successfully
transplanted. Mean duration of LVAD support was 215±143 days (range 71-
455). While on the LVAD all patients were in NYHA functional class I and
showed good exercise performance as reported before (6). After the initial
postoperative period, all cardiac medication had been stopped, except for low-
dose aspirin. Written informed consent was obtained from all patients.
Table 1. Characteristics of LVAD patients
Male 12
Female 1
Age (y) 34±13 (range 18-55)
DCM / IHD 6 / 7
LVEF (%) 14±5
MAP (mmHg) 64±13
IABP/other support 6
Duration of LVAD support (days) 215±143
Immunohistochemical analysis
Large transmural myocardial biopsies after LVAD support, at the time of heart
explantation were taken from the LV, IVS and RV. All biopsies were directly
fixed in buffered formalin, embedded in paraffin and routinely processed on 5
µm sections. Standard immuno-histochemical analysis was performed using a
three step avidin- biotin peroxidase reaction. In brief, sections were
deparaffinised , rehydrated and endogenous peroxidase was blocked using a
solution of methanol and hydrogenperoxide. Primary antibodies were applied
to the sections for 1 hr and subsequently demonstrated using a biotinylated
horse IgG anti mouse IgG and HRP labeled streptavidin. Immunovisualisation
was performed using DAB reagent and counterstaining with Mayer
hematoxilin. Sections were dehydrated, cleared and embedded in Pertex.
Primary monoclonal antibodies used in this study were: anti sarcomere actin
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(Sigma, Zwijndrecht, the Netherlands), myosin slow (Sigma), tropomyosin
(Sigma), troponin T (Sigma) and troponin C (Novocastra, Newcastle upon Tyne,
UK). Antigen retrieval by boiling sections in citrate buffered solution for 15 min
was performed to the sections for all antibodies except myosin. Sections for
myosin incubation were proteolytically digested with pepsin for 15 min.
All slides contained large transmural biopsies  and were examined in a blinded
fashion by three investigators. In these biopsies all longitudinally arranged
cardiomyocytes were analyzed. In case of ischemic heart disease only surviving
myocytes were studied; the necrotic area was not taken into consideration. A
grading system was used, as reported before (15):
1. Almost all myocytes show a distorted architecture with absence of cross-
striation.
2. Some normal myocytes with cross-striation are present; most of the
myocytes, however, are abnormal.
3. Normal myocytes with cross-striation along with myocytes without cross-
striation or myocytes without antigen staining over the full length of the
contractile filament.
4. Some myocytes with distorted architecture; most of the myocytes however
are normal.
5. Almost all myocytes show normal architecture and cross-striation.
To test for inter- and intra-observer variability, kappa value of reliability was
determined.
Furthermore, we investigated the potential damage of a biopsy forceps on the
immunohistochemical morphology of the contractile proteins, and if the
histologic findings of the myofilaments in these small biopsies were
representative for larger biopsies. For this purpose, in 5 patients additional
biopsies of the right ventricular side of the IVS were taken with a Caves
bioptome directly  after explantation of the heart and compared to the
corresponding large IVS biopsies. The immunohistochemical protocol for these
biopsies was the same as for the larger biopsies.
Hemodynamic measurements
To be informed about the left and right ventricular filling pressures, we
performed Swan-Ganz catheterisation in all patients right before LVAD
implantation and 6-8 weeks after implantation, when organ function had
recovered and the patients  were fully rehabilitated. The measurements after
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LVAD implantation were performed with the device operated in the “auto”
mode.
Statistical analysis
All data are presented as the mean ± SD. The grading of the
immunohistochemical data on the contractile proteins in the 3 different
biopsies were compared by two-tailed paired Student-t test and Friedman rank
test.  Comparison between DCM and IHD was made by an unpaired Student-t
test. Inter-and intra-observer variability was tested using Kappa analysis. All
data were calculated with SPSS 8.0 for windows. A p value < 0.05 was
considered significant.
Results
Grading of the contractile proteins
The gradings of the contractile proteins for LV, IVS and RV, are shown in figure
1. For actin they amounted to: 2.4±0.9, 2.0±1.1 and 3.0±1.0, respectively,
and for myosin: 4.2±1.2, 4.0±1.3 and 4.3±1.0. Tropomyosin showed the
following gradings: 3.5±0.9, 3.0±0.9 and 3.7±1.0. For troponin T they were
3.2±1.0, 3.1±1.0 and 3.6±0.9, respectively, and for troponin C: 3.2±1.0,
2.9±0.9 and 3.5±0.9. There were no significant differences between the
gradings of the LV, IVS and RV.
Figure 1: Grading of the contractile proteins in myocytes of LV, RV and IVS after LVAD
support showing identical findings throughout the heart. For explanation of the grading
system see text.
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Typical examples for actin and myosin are shown in figure 2 and 3.
Comparison between patients with DCM and IHD showed that the grading of
the contractile proteins did not differ between these groups (Fig.4). The inter-
and intra-observer kappa values were 0.57 and 0.63, respectively, indicating
fair agreement.
Figure 2: An example of actin staining in the LV (A), RV (B), and IVS (C) (all grade 2)
(original magnification 100x).
Figure 3: An example of myosin staining in the LV (A) (grade 4), RV (B) (grade 5) and
IVS (C) (grade 4) (original magnification 100x).
Figure 4: Comparison of the grading of the contractile proteins between patients with
DCM and IHD showing no difference.
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Analysis of the 5 small biopsies from the IVS, taken with the Caves bioptome,
showed that also in these biopsies the contractile myofilaments could be well
assessed. No mechanical damage of the myofilaments, by the bioptome, was
visible. Comparison with the corresponding large
biopsies showed that the morphology of the contractile proteins was identical
in the small and the large biopsies (Fig. 5).
Figure 5: Comparison of small biopsies taken with a diagnostic bioptome (A and C) and
large transmural biopsies (B and D) from the same heart. A and B actine staining (grade
2); C and D myosin staining (grade 5). (original magnification 100 x)
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Hemodynamic data
Before LVAD implantation all patients demonstrated severely compromised
hemodynamics (Fig. 6). Mean pulmonary capillary wedge pressure was 25±6
mm Hg, mean arterial pressure 64±13 mm Hg with a mean cardiac output of
3.5±1.1 L/min. Right atrial pressure was also increased: 11±6 mm Hg (range
1-23), with normal pulmonary vascular resistance, 170±90 dynes.sec.cm –5 . In
this patient group 8 out of the 13 patients had right atrial pressures higher than
10 mm Hg at the time of LVAD implantation, suggesting RV failure. Directly
after LVAD implantation, 5 out of 13 patients had symptomatic RV failure
resulting in inadequate filling and low output of the device, for which treatment
with positive inotropic and vasoactive agents was instituted successfully. There
appeared to be no relation between the grading of the contractile proteins after
LVAD support in individual patients and the left and right ventricular filling
pressures before LVAD implantation, nor with clinical symptomatic right
ventricular failure shortly after LVAD implantation.
Figure 6: Hemodynamic data at the time of LVAD implantation and after implantation
when the patients were fully rehabilitated. Results are presented as mean ± SD. PCW
= pulmonary capillary wedge pressure, RA = right atrial pressure, CO = cardiac
output.
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After the direct postoperative period, when all patients were fully mobilized, no
clinical RV failure was apparent. Hemodynamic measurements at that time
showed low filling pressures of both right and left ventricles (Fig. 6). Right atrial
pressure was 3±3 mm Hg (p< 0.004 vs. pre-LVAD), pulmonary capillary
wedge pressure 5±3 mm Hg (p< 0.0001 vs. pre-LVAD), pulmonary artery
pressure 19/8, mean 12 mm Hg. Cardiac output was 6.3±1.1 L/min (p<
0.0001 vs. pre-LVAD). This means that the LVAD was functioning adequately
and emptied the LV completely. Furthermore, RV function was completely
restored.
Discussion
The main finding in this study of relatively young patients supported with a
LVAD for 215±143 days is the identical morphology of the contractile proteins
in LV, IVS and RV, despite the fact that only the LV is supported. Furthermore,
biopsies taken with a diagnostic bioptome show a good quality of histologic
findings, similar to the much larger transmural biopsies. The staining pattern of
the contractile proteins in this study is in agreement with our previous study
(15): an intermediate grading for the thin contractile proteins, with actin
showing the lowest grading and a higher score for the thick contractile protein
myosin. In this patient group we could not demonstrate a relationship between
increased RV filling pressures before LVAD implantation, or symptomatic RV
failure directly after implantation, and the grading of the contractile proteins of
the RV and IVS after long-term assist. This could be explained by the long
duration of LVAD support in this patient group (215±143 days). The similar
morphologic structure of the contractile myofilaments of LV and RV in this
study suggests that cardiac recovery after LVAD support, if it occurs, appears to
be the same, throughout the whole heart.  Our findings seem to be in contrast
with those of Barbone et al (14), who demonstrate  differential left and right
ventricular reverse remodeling after LVAD implantation, suggesting that
reduction of mechanical load is a primary factor underlying this process. In that
study reverse remodeling was studied by looking at LV and RV myocyte size,
SERCA 2a content and force-frequency relations of isolated superfused
trabecula. An important difference with our study is that in the study of
Barbone et al. (14) the LVAD support time was considerably shorter (77±71 vs.
215±143 days) and right atrial pressure during LVAD support much higher
(11±6 vs. 3±3 mm Hg) than in our study, suggesting that right ventricular
function had not completely been recovered. In our patient group 8 out of 13
patients had signs of right ventricular failure before LVAD implantation. Five
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out of the 13 patients had symptomatic right ventricular failure during and
directly after LVAD implantation. Right ventricular failure is one of the main
complications in LVAD implantation, occurring in about one third of the
patients (3). The hemodynamic data in our study, after LVAD implantation,
suggest that RV function had recovered sufficiently. It is in this situation that we
demonstrate identical morphology of the contractile proteins in LV, IVS and
RV. Regarding the data of Barbone et al. (14) the differences of the results
between RV and LV in that study were small. Furthermore, in the expression of
SERCA 2a and the force-frequency relation, they used normalized ratio’s to
demonstrate a difference between RV and LV results, ignoring the pre-existing
absolute difference between RV and LV. Therefore, we think there is still no
definite answer to the question of whether the process of reverse remodeling is
mainly caused by hemodynamic unloading or by the normalized biochemical
milieu. LVAD support results in improvement of neurohormonal activation (16-
18) which might be responsible for reverse remodeling throughout the whole
heart. On the other hand hemodynamic unloading of the LV may also influence
RV function. Both beneficial and detrimental effects have been reported (19).
The decreased LV volume during LVAD support may alter the septal and LV
contributions to RV contraction (20). The main effect of LVAD support,
however, is improvement of RV function, by decreasing RV afterload (19,21).
The observation of identical morphology of the contractile proteins in LV, IVS
and RV in this study was done in patients who were not weaned from the
device; all were transplanted, except for one patient who died before
transplantation. Therefore, from this study we can not definitely conclude  that
the results would have been the same in patients demonstrating enough reverse
remodeling to allow for LVAD removal. We merely demonstrated identical
morphology of the contractile filaments in LV and RV after a rather long period
of LVAD support, in the absence of persistent RV failure. In the present study,
we have not examined if the same holds true in case of persistent RV failure or
after a shorter period of LVAD support; therefore, this remains a matter of
speculation.
Conclusion
This study demonstrates that the morphology of the contractile myofilaments
after support with a LVAD, in the absence of RV failure, is identical in LV, IVS
and RV. Furthermore, small biopsies taken with a diagnostic bioptome are
representative for the histologic findings of the myofilaments in larger biopsies
and do not show damage by the bioptome. Therefore, with regard to the
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morphology of the contractile myofilaments, prospective biopsies of the RV
may be a way of monitoring reverse remodeling of the LV during LVAD
support.
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The aim of this thesis was to study the role of left ventricular mechanical
support in end-stage heart failure, particularly if this device can be used as an
alternative to heart transplantation, or as a treatment option leading to recovery
of cardiac function.
The impact of heart failure in medicine is expanding. The annual increase in
prevalence suggests a growing epidemic, mainly caused by aging of the
population (1). On the other hand, this growing epidemic, seen in the
perspective of the greatly improved management of virtually all forms of heart
disease that lead to heart failure, seems to be a paradox (2). It has to be
remembered, though, that many forms of heart disease that can now be
successfully treated, are not really cured. For example, premature death from
hypertension and acute myocardial infarction are prevented, allowing for
chronic adaptive changes, eventually leading to heart failure (2).
The pathophysiology of heart failure is very complex and no single conceptual
paradigm has withstood the test of time (3). Initially the “cardiorenal model”
was applied in which heart failure was viewed as a problem of excessive salt
and water retention that was caused by abnormalities of renal blood flow (4).
Later, the “hemodynamic model” developed, centering around reduced cardiac
output and excessive peripheral vasoconstriction (4). Subsequently, the
“neurohormonal model” was introduced in which heart failure progresses as a
result of the overexpression of biologically active molecules that are capable of
exerting toxic effects on the heart and the circulation, contributing to disease
progression independently of the hemodynamic status of the patient (3). All
these models laid the foundation of important therapeutic strategies, but
especially the neurohormonal model greatly improved the conceptual thinking
of heart failure. Furthermore, it contributed to the introduction of ACE-
inhibitors and later ß-blockers leading to a major  improvement of prognosis in
heart failure (5-11). Later, also inflammatory cytokines, endothelin and
oxidative stress were introduced in this model (12). All these pathways, as well
as increased wall stress, can give rise to apoptotic cell death, progressive
remodeling, and altered gene expression, resulting in progression of myocardial
dysfunction (13).
But even this complex neurohormonal model fails to completely explain
disease progression in heart failure (3). This can be inferred from the Kaplan-
Meier survival curves of ACE-inhibitor and ß-blocker trials. The curves from
treated and non-treated patients clearly begin to diverge at 6 months, to
become parallel again between 18 and 48 months. This suggests that there may
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be an attenuation or loss of effectiveness of neurohormonal antagonism as heart
failure progresses. This may be explained by incomplete inhibition of the renin-
angiotensin or the adrenergic systems in heart failure, or by alternative
metabolic pathways for neurohormones that are not antagonized by the current
medications (3). However, the addition of an angiotensin receptor blocker to an
ACE inhibitor to block remaining angiotensin II levels completely, as was done
in the Val-HeFT study (14),  surprisingly, did not result in a further decrease in
mortality. Patients on a combination of ACE-inhibitor and ß-blocker who
received additional angiotensin receptor blocker, did even worse on the end
points mortality and morbidity (14). Other investigations on endothelin
receptor antagonists and TNFα binding proteins have not been very
encouraging either (15). Therefore, the assumption that the addition of other
antagonists will be effective cannot be taken for granted and the recent results
of the above mentioned trials may suggest that the string of successes with
neurohormonal antagonists may have run its course (15). Research on the
optimal dose and combination of neurohormonal antagonists has to continue
but one has to bear in mind that it will be increasingly difficult to attain
additional survival benefit on top of that already achieved with the present
antagonists.
Fundamental aspects of end-stage heart failure
The treatment of patients with end-stage heart failure with a LVAD entails the
unique opportunity to obtain myocardial biopsies at two points in time: at the
time of LVAD implantation, when the hemodynamic situation is severely
compromised, and after a period of unloading, at the time of heart
transplantation. In that same period blood samples can be taken to monitor
“peripheral” effects of neurohormonal activation during unloading of the left
ventricle. Maybe this model can help contribute to the understanding of the
complex pathophysiology of heart failure in man. Chapter 4 and 5 show some
results. Chapter 4 focuses on the morphology of the contractile proteins in
cardiomyocytes. For this study we used immunohistochemistry, which enables
the examination of large biopsies, in contrast to electron microscopy in which
only very small biopsies can be studied. Considering the widespread variation
in myocyte histology which we observed, with areas showing an almost normal
structure adjacent to areas with severe morphological disorganization, the use
of electron microscopy may underestimate the severity of the morphological
alterations. In the biopsies of the patients with severe heart failure, at the time
of LVAD implantation, we found an impressive disturbance of the normal
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staining pattern of titin, actin and its related proteins tropomyosin, troponin C
and T. Myosin in contrast, showed normal morphology. The disturbance of the
staining pattern of the thin contractile proteins was more impressive than would
be expected from the routine HE staining. Potentially, this technique could be
used to make myocardial biopsies in heart failure patients more informative.
The abnormal staining pattern of the thin contractile filaments with specific
monoclonal antibodies suggests that the expression of the contractile proteins is
disturbed in the failing human heart (16), and that heart failure will result in
loss of contractile elements (17). This has been confirmed using electron
microscopy, which shows large cellular areas containing only mitochondria,
ribosomes and glycogen (17). It seems obvious that these changes of the
contractile proteins result in a decrease of myocyte contractile function. The
regulators of these contractile protein alterations are not known but are
probably numerous. Cleavage of membrane-associated actin has been reported
in human neutrophils during apoptosis (18).  Therefore, it can be speculated
that activation of the apoptotic cascade in heart failure may directly result in
damage to actin and its related contractile proteins in the cardiomyocytes.
Apoptotic cardiomyocyte death, on the other hand is limited by the presence of
FLICE Inhibitory Protein (FLIP) which inhibits death domain related apoptosis.
This protein is abundantly present in the heart, as is shown in chapter 5. After
LVAD support the apoptotic process is less activated, probably through
decreased neurohormonal stimulation, and by a reduction in myocardial stretch
as a result of left ventricular unloading. This may result in partial restoration of
thin contractile protein morphology. Pharmacological intervention to improve
this process appears an interesting area of future research.
Chapter 5 deals with apoptotic cell death and its regulators. Apoptosis is
thought to play a role in ventricular remodeling (19), although controversy
exists about its importance (20). Despite many studies performed on this
subject it is still not clear if progressive myocyte loss precedes and causes
progressive cardiac dilatation, or whether, alternatively, progressively abnormal
myocyte function leads to end-stage cardiac dilatation, which then triggers cell
loss (21). Progressive myocyte loss may either constitute an adaptation to
preserve function of less-affected cells, or it may be a maladaptation resulting in
further dilatation (21). The discussion about the importance of apoptosis in the
progression of heart failure is further complicated by the limitations of the
techniques used for detecting apoptosis. The frequently used TUNEL method is
a very sensitive but not a very specific technique, since oncotic and autolytic
cells, as well as living cells undergoing DNA repair or RNA synthesis may also
be labeled (20). In our study we tried to substantiate the incidence of apoptosis
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by also evaluating the caspase-3 expression, which constitutes the final
common step in the apoptotic cascade. Our observations indicate that the very
high percentage of TUNEL positive cardiomyocytes which we saw in two
patients, was not caused by apoptosis, because it was not accompanied by high
caspase-3 expression.
In patients with end-stage heart failure we noted a low incidence of apoptotic
cardiomyocytes (0.8 %) combined with low caspase-3 expression. Mediators of
apoptosis and their receptors were all present. Considering the ample presence
of conditions for apoptosis, the low incidence of cardiomyocyte cell death
suggests that to a certain extent these cells are protected from apoptotic cell
death. In cardiomyocytes the apoptosis-inhibitor FLIP was abundantly present,
and comparable to the level in non-failing hearts. In endocardial and
endothelial cells, showing a high incidence of TUNEL expression, FLIP
expression was much lower. Therefore, we think that FLIP is an important
inhibitor of cardiomyocyte apoptotic cell death in heart failure. Other inhibitors
of apoptosis, like NF-κB may also influence the delicate balance between cell
death and survival in heart failure, because in animal studies it has been
suggested that  the cytotoxic effect of TNFα is dependent on the blocking of
NF-κB (22). This transcription factor has been recently investigated in patients
undergoing LVAD implantation showing a significant decrease in the number
of NF-κB positive cardiomyocyte nuclei after LVAD support (23).
To return to the conundrum of end-stage heart failure (21), the results in the
studies of the LVAD patients show widespread alterations in morphology of the
thin contractile proteins and titin (chapter 4) and only a low incidence of
cardiomyocyte apoptosis, despite ubiquitous mediators (chapter 5). These
findings may suggest that deterioration of myocyte function contributes more to
the progression of heart failure than reduction in myocyte number. The
predominance of apoptotic cardiomyocytes and TNFα in the subendocardial
region of the heart, a preferred site for ischemia in the myocardium, may
suggest that secondary ischemia, caused by increased wall tension as a
consequence of dilatation of the heart, may be central in cardiomyocyte cell
death. This ischemia activates death receptor and mitochondrial pathways of
apoptosis, as well as regulatory proteins like FLIP and NF-κB. In the end the
balance in the pro-and anti-apoptotic factors determines the extent of apoptosis.
Progressive cardiomyocyte cell death in itself contributes to the decline of the
contractile function and subsequent cardiac dilatation. This adds to the vicious
circle.
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Therapeutic options in end-stage heart failure
Complete antagonism of presently recognized neurohormonal activation does
apparently not result in complete abrogation of disease progression. Therefore,
other options for end-stage HF are warranted. Heart transplantation is the only
treatment option that provides both a significant survival advantage and a
substantial improvement in functional class (24). Therefore, it still deserves an
important place in the treatment of patients with end-stage heart failure,
although the number of donor hearts decreases year by year (25). In the
Netherlands it is thought that this may be partly attributed to insufficient donor
recognition and logistical problems in the donor hospitals. Considering the
enormous efforts and the financial investments put into it, it appears very
unlikely that this should be the only cause. Most discussions about the potential
number of donors available in the Netherlands are confused by the
entanglement of potential organ and tissue donors. In contrast to cornea and
skin donation, heart donation is only possible in patients with severe
neurological damage eventually resulting in brain-death. The treatment of these
patients has been optimized over the years, aimed at preventing brain death.
Furthermore, impressive safety precautions have been introduced in the car
industry, like safety belts and airbags, combined with speed-limits, evidently
reducing the number of casualties. Therefore, it is likely that the reduction in
the number of donor hearts allocated is the result of a real reduction of
available donor organs. It is evident that every effort has to be made to increase
the number of the available donor organs and to optimize their usage, but it is
realistic to assume that in this way only a minority of heart failure patients can
be treated, like a drop in the ocean. That is why alternative treatment options
have to be explored.
Mechanical support in end-stage heart failure
Mechanical support of the failing heart is almost as old as heart transplantation
itself (26), but, only recent improvements of the devices have turned this into a
regular treatment modality (27, 28). Implantable left ventricular assist devices
are now mainly used as a bridge to transplantation, but the growing experience
with these devices suggests that they may also be used as an alternative to heart
transplantation (29).
In 1993 we started the implantation of LVAD’s in the Heart Lung Center
Utrecht, as part of our heart transplantation program. The results of this bridge
to transplantation program are presented in chapter 2. The results are very
encouraging with a long-term survival of 79 %. This is especially promising
considering the very poor condition of the patients at the time of LVAD
General discussion
133
implantation. Infections do remain an important problem with this technology,
which is partly attributable to the external driveline. Frequent mechanical
problems limit the longevity of the device used in this study (HeartMate), as
was illustrated by the Randomized Evaluation of Mechanical Assistance for the
Treatment of Congestive Heart Failure (REMATCH) study group, which showed
a probability of device failure of 35 % at 24 months (30). Nevertheless, this
study is the first to show that mechanical support with a LVAD in selected
patients with advanced heart failure resulted in substantial improvement in
survival and may be an acceptable alternative to transplantation (30).
It is also important to know the improvement in exercise capacity after
implantation of a LVAD, as a parameter of the quality of life with mechanical
support. Therefore, we performed exercise testing with respiratory gas analysis
at several points in time after LVAD implantation. The results, shown in chapter
3, confirm that exercise capacity increases over time and, at 12 weeks after
LVAD implantation, is comparable to that at 12 weeks and one year after heart
transplantation. With regard to exercise capacity a LVAD is fully compatible
with activities of normal daily life, apart from the inconvenience of the console
or the battery pack.
As mentioned above, mechanical problems with the HeartMate are an
important item, limiting the large scale introduction of this device as an
alternative to heart transplantation. It is hoped and expected that the newer
devices using rotary axial flow pumps and magnetically suspended centrifugal
pumps, like the HeartMate II and III and the Jarvik 2000, will offer greater
durability with less wear and tear. A complicating factor of those devices is the
lack of the textured blood-contacting surface of the HeartMate, which
potentially increases the thrombo-embolic risk and requires anticoagulation.
The same holds for the new totally implantable artificial heart (Abiocor), which
was recently implanted in seven patients of whom already five have died after
several weeks on the device. When the problems of durability, infections and
thrombo-embolism  with mechanical support in heart failure have been solved,
we are well on the way to the use of  mechanical support as a realistic
alternative to heart transplantation. LVAD’s may solve the problem of donor
scarcity, and eliminate the adverse effects of immunosuppression. In addition,
unlike transplantation, implantation of the device can be planned at an optimal
time in the patient’s course. What the effect of this policy will be on costs has
to be analyzed and society has to decide if it can afford this kind of therapy
(31).
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Bridge to recovery
It has been suggested to use mechanical support as a bridge to recovery of
cardiomyocyte function in severe heart failure, through a process called
“reverse remodeling”. This seems a plausible thought at first glance,
considering the impressive hemodynamic improvement of the patients after
implantation of a LVAD. Anecdotal reports of patients weaned from the assist
device are available (32-34), although long term results are often lacking. Other
reports question the use of a LVAD as a bridge to recovery (35,36), except for
potential curable diseases like myocarditis and peripartum cardiomyopathy.
Chapter 4 and 5 also deal with this subject, showing a persistence of
cardiomyocyte hypertrophy after LVAD support, although cardiomyocyte cross
sectional area decreased 36 %. The immunohistochemical staining pattern of
the contractile filaments improved, but overall widespread areas of abnormal
staining pattern persisted. After LVAD support the staining pattern within each
cardiomyocyte appeared to be more homogeneous. Between different
cardiomyocytes, however, the variability in staining pattern persisted. This
resulted sometimes in the alternation of myocytes staining normally, with
myocytes showing abnormal or absent staining, in the same contractile fiber.
This suggests that recovery for the individual cardiomyocyt is an all-or-nothing
phenomenon, exhibiting either complete recovery or complete disappearance
of contractile filaments. Furthermore, after support most patients showed an
increase of interstitial tissue, probably fibrosis.
An increase of fibrosis together with the deprivation of contractile proteins from
myocytes will undoubtedly have a negative impact on overall cardiac
contractility and electrical conduction, creating conditions for re-entry, which
will increase the risk for lethal arrhythmias (37). Furthermore, also diastolic
function may be affected adversely.
Besides the persistence of both cardiomyocyte hypertrophy and severe
structural myocyte damage, the incidence of apoptotic cardiomyocytes in the
patients with severe heart failure decreased after unloading (0.8 % of
cardiomyocytes TUNEL positive before LVAD, 0.1 % positive after support; p<
0.01). As mentioned before, this may be attributed to the decrease of wall
tension due to unloading of the left ventricle, and the decrease of
neurohormonal activation after LVAD support. The apoptotic mediators and
their receptors, however, all remained present, even if one assumes that the
level of expression may have decreased a little. Immunohistochemistry may not
be sensitive enough to detect minor differences. Therefore, the substrate for
cardiomyocyte apoptotic cell death remains existent, despite the improved
hemodynamics of the patients.
General discussion
135
These data suggest that after LVAD support some recovery at the cellular level
in the failing heart is taking place, but that we are still far from “treating” heart
failure with an assist device. The idea that heart function can recover after
unloading the left ventricle is based on the very old concept that rest is
beneficial for patients with heart failure (38). Heart failure therapy, however,
has changed dramatically over the years. The clinical picture of heart failure,
for example, is dominated by impaired exercise performance, partly caused by
skeletal muscle abnormalities (39). Many studies have demonstrated a
beneficial effect of exercise training in heart failure patients (40) with
improvement of skeletal muscle metabolism (41-44). This underscores that, in
contrast to the previous mentioned old ideas, complete rest is not wholesome
for disturbances of skeletal muscle metabolism in heart failure. Most probably,
this applies to cardiac muscle as well: the mere unloading does not result in
long-term improvement of cardiac function, except in those patients who
received a LVAD for potentially curable diseases like myocarditis. Alternative
treatment protocols, combining mechanical support with pharmacological
therapy, growth hormone, gene therapy, or myocyte or stem cell
transplantation, may hold the key to better long-term results (45,46). In these
strategies monitoring of recovery is essential. Staining of the contractile
myofilaments in myocardial biopsies by immunohistochemistry, as shown in
chapter 4 may help to demonstrate sufficient recovery of cardiomyocyte
histology, to allow for device removal. As most endomyocardial biopsies are
taken from the right ventricle by a jugular access, using modified Caves
bioptomes, it is essential to demonstrate that the histology of right ventricular
biopsies is representative of the  left ventricle as well.
In chapter 6, it is demonstrated that in patients showing only partial recovery,
this is actually the case. Therefore, we postulate that in this patient group,
which has gone through a long period of LVAD support, right ventricular
biopsies can be used to monitor recovery in the left ventricle, provided there is
no right ventricular failure. This will require sequential biopsies to monitor the
process of recovery over time.
The concept, of using mechanical support of the failing left ventricle for
temporary circulatory assistance, meanwhile  taking the opportunity to provide
intensive therapy aimed at reversal of remodeling, seems appealing. It will
require elaborate research of the process of reverse remodeling and of the
mediators amenable as targets for intervention. Furthermore, the optimal mode
of monitoring recovery has to be determined and above all, long-term recovery
has to be confirmed.
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Mechanical support in end-stage heart failure has rapidly become  very
important. We are now at the brink of  a new era in the treatment of patients
with severe heart failure. Mechanical support has already established a place as
bridge to heart transplantation; it is to be expected that very soon it can also be
applied as an alternative to heart transplantation in selected patients. Hopefully,
in the future it will be used as a bridge to recovery of cardiac function, in
combination with other therapeutics aimed at reverse remodeling. Furthermore,
mechanical support offers a unique opportunity to extend basic research on
severe human heart failure, by the availability of myocardial tissue at several
points in time, before and after unloading of the heart.
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The aim of this thesis was to study the role of left ventricular mechanical
support in end-stage heart failure, particularly if this device can be used as an
alternative to heart transplantation, or as a treatment option leading to recovery
of cardiac function.
Chapter 1 is a general introduction that provides an overview of some
clinical aspects of heart failure with emphasis on the role of heart
transplantation and mechanical circulatory support in end-stage heart failure.
Furthermore, the complex pathophysiology of heart failure is discussed,
focussing on the process of remodeling and the importance of apoptosis and
cytokines, like tumor necrosis factor alpha.
Chapter 2 reports the results of the use of the HeartMate left ventricular
assist device as a bridge to transplantation in the University Medical Center
Utrecht. These results are very encouraging. Despite the very poor condition of
the patients at the time of implantation of the left ventricular assist device
(LVAD), 33 of the 38 patients (87%) who underwent LVAD implantation,
survived the perioperative (30 day) period. In the early postoperative period
right ventricular failure was an important problem, resulting in the death of two
patients in this group. After this period the main problems are infections and
mechanical problems, limiting the long-term use of this device. Twenty-six
patients (76%) underwent heart transplantation after a duration of LVAD
support of 206±129 days.
Chapter 3 deals with the exercise performance of patients while on an
LVAD. Exercise capacity increases over time, and at 12 weeks after LVAD
implantation, peak VO2 is comparable to that at 12 weeks and one year after
heart transplantation (peak VO2: 22.8±5.3, 24.6±3.3 and 26.2±3.8
ml/kg/min, respectively). Therefore, with regard to exercise capacity an LVAD
is fully compatible with activities of normal daily life, apart from the
inconvenience of the console or the battery pack, and holds a promise as a
potential alternative for heart transplantation.
Chapter 4 describes the histologic features of cardiomyocytes, with
emphasis on the contractile proteins, in patients with end-stage heart failure
undergoing LVAD implantation. In 14 patients myocardial biopsies taken at the
time of LVAD implantation and after explantation, at the time of heart
transplantation were compared using routine hematoxylin-eosin staining and
immunohistochemistry with antibodies against the contractile proteins. At the
time of LVAD implantation widespread distortion of the staining pattern of the
thin contractile proteins and titin was seen. In contrast, myosin staining pattern
was preserved. After LVAD support, during a period of 213±135 days, the thin
contractile proteins and titin showed improvement, but no normalization.
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Cardiomyocyte cross-sectional area decreased 36% after LVAD support, but
also did not normalize. The persistence of severe structural myocyte damage in
this study group does not support complete recovery of myocyte histologic
features after a period of unloading of the heart by LVAD support.
Chapter 5  focuses on cardiomyocyte cell death in patients with end-
stage heart failure, before and after LVAD support. In 17 patients, myocardial
biopsies at the time of LVAD implantation and after explantation, at the time of
heart transplantation, were examined by TUNEL reaction to detect
cardiomyocyte apoptosis. Furthermore, immunohistochemistry was used to be
informed about regulators of apoptotic cell death. Before LVAD support
apoptosis incidence was low (0.8% of cardiomyocytes), further decreasing after
support (0.1% of cardiomyocytes). The apoptosis inducing mediators and their
receptors were all present before and after LVAD support. The apoptosis
inhibitory protein FLIP was widely expressed in cardiomyocytes before and
after LVAD support, with m-RNA levels comparable to that in normal controls.
This may suggest that FLIP is an important factor in the prevention of
cardiomyocyte apoptosis.
Chapter 6 reports the comparison of the morphology of the contractile
proteins in biopsies of the left- and right ventricle and the interventricular
septum to investigate if right ventricular biopsies might be used to monitor
reverse remodeling in the left ventricle. This was done because right ventricular
biopsies can be easily obtained by a jugular vein approach. In 13 patients with
end-stage heart failure, myocardial biopsies after LVAD support, at the time of
heart transplantation were compared, using immunohistochemistry with
antibodies against the contractile proteins. The staining pattern of these
biopsies from the left- and right ventricle and from the right ventricular side of
the interventricular septum was identical. Furthermore, small biopsies taken
with a diagnostic bioptome were representative for the histologic findings of
the myofilaments in larger biopsies. With regard to the morphology of the
contractile proteins, prospective biopsies of the right ventricle may be a way of
monitoring reverse remodeling of the left ventricle during LVAD support.
Chapter 7 is a general discussion of the results of the investigations
included in this thesis. Mechanical circulatory support has already established
an important place as bridge to transplantation. Patients with severe end-stage
heart failure, facing imminent death, can be successfully kept alive with an
LVAD, until a donor heart comes available. This does not solve, however, the
shortage of donor organs. Probably, mechanical circulatory support can be
used in the near future as an alternative to heart transplantation. In this way the
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problem of the scarcity of donor organs can be overcome. The use of
mechanical support as a bridge to recovery of cardiac function in end-stage
heart failure is presently highly experimental and unpredictable. Only
potentially curable diseases, like myocarditis may demonstrate enough
recovery, allowing device removal. The concept, of using mechanical support
of the failing left ventricle for temporary circulatory assistance, meanwhile
taking the opportunity to provide intensive therapy aimed at reversal of
remodeling, seems appealing. It will require elaborate research of the process
of reverse remodeling and of the mediators amenable as targets for
intervention. Furthermore, the optimal mode of monitoring recovery has to be
determined and above all, long-term recovery has to be confirmed.
Chapter 9
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Dit proefschrift beschrijft de rol van mechanische ondersteuning van de linker
ventrikel bij eindstadia van hartfalen, met name om te beoordelen of dit ook als
alternatief voor harttransplantatie gebruikt kan worden, dan wel als
behandelingsmogelijkheid om de hartfunctie langdurig te laten herstellen.
Hoofdstuk 1 is een algemene inleiding, waarin een overzicht wordt
gegeven van een aantal klinische aspecten van hartfalen, toegespitst met name
op harttransplantatie en mechanische ondersteuning van het hart bij eindstadia
van hartfalen. Tevens wordt de complexe pathofysiologie van hartfalen
besproken, in het bijzonder het proces van remodeleren en het belang van
apoptose (geprogrammeerde celdood) en cytokines (regelaars van onder andere
celgroei en celdood), met name tumor necrosis factor alpha.
Hoofdstuk 2 beschrijft de ervaring in het Universitair Medisch Centrum
Utrecht met de HeartMate, een linker ventrikel steunhart, gebruikt als
overbrugging naar harttransplantatie. De resultaten zijn zeer bemoedigend.
Ondanks de zeer slechte algemene conditie waarin de patiënten zich
bevonden op het moment van implantatie van het steunhart (Left Ventricular
Assist Device, LVAD), overleefden 33 van de 38 patiënten (87%) de
perioperatieve periode (30 dagen). In de vroeg postoperatieve periode is
rechter ventrikel falen een groot probleem, hetgeen heeft geresulteerd in het
overlijden van twee patiënten. Na deze periode zijn de belangrijkste
complicaties infecties en mechanische problemen van het steunhart. Hierdoor
wordt met name langdurig gebruik beperkt. Zesentwintig patiënten (76%)
ondergingen een harttransplantatie na een periode van 206±129 dagen aan
het steunhart.
Hoofdstuk 3 gaat over het inspanningsvermogen van patiënten aan het
steunhart. Het inspanningsvermogen neemt toe in de loop der tijd, waarbij de
maximale zuurstofopname tijdens inspanning (piek VO2), 12 weken na LVAD
implantatie, overeenkomt met die van 12 weken en van een jaar na hart
transplantatie (piek VO2: 22.8±5.3, 24.6±3.3 and 26.2±3.8 ml/kg/min,
respectievelijk). Wat betreft het inspanningsvermogen is een steunhart geschikt
om normale dagelijkse bezigheden te verrichten, hoewel de aandrijvingconsole
of de draagbare accu’s wel enig ongemak met zich mee kunnen brengen. Met
betrekking tot het inspanningsvermogen kan mechanische ondersteuning dus
als een bruikbaar alternatief voor harttransplantatie worden gezien.
Hoofdstuk 4 beschrijft de histologische kenmerken van de
cardiomyocyten, in het bijzonder de contractiele eiwitten, bij patiënten met
ernstig hartfalen, die een LVAD implantatie ondergingen. Bij 14 patiënten
werden myocard biopten genomen ten tijde van de LVAD implantatie. Deze
werden vergeleken met biopten genomen na explantatie, tijdens de
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harttransplantatie. De biopten werden beoordeeld middels routine
hematoxyline-eosine kleuring en met behulp van immunohistochemie, gebruik
makend van antistoffen tegen de contractiele eiwitten. De biopten afgenomen
tijdens de  LVAD implantatie vertoonden uitgebreide afwijkingen van het
kleuringpatroon van de dunne contractiele eiwitten en titin. Het beeld van
myosine, het belangrijkste bestanddeel van de dikke contractiele eiwitten,
daarentegen was vrijwel geheel normaal. Na LVAD ondersteuning, gedurende
213±135 dagen toonden de dunne contractiele eiwitten en titin verbetering,
echter geen normalisatie. De oppervlakte van de dwarsdoorsnede van de
cardiomyocyten ten tijde van de LVAD implantatie was ruim twee maal zo
groot dan bij normale cardiomyocyten. Na LVAD ondersteuning nam deze
oppervlakte weliswaar 36% af, maar normaliseerde evenmin. Het persisteren
van belangrijke structurele myocyt schade in deze patiënten groep pleit tegen
een volledig herstel van de histologische eigenschappen van de cardiomyocyt,
na een periode van LVAD ondersteuning
Hoofdstuk 5  houdt zich bezig met dood van cardiomyocyten in
patiënten met een eindstadium hartfalen, voor en na LVAD ondersteuning. Bij
17 patiënten werden myocard biopten voor en na LVAD implantatie
onderzocht op het voorkomen van apoptotische cardiomyocyten, middels de
TUNEL reactie. Tevens werd met behulp van immunohistochemie geprobeerd
een indruk te krijgen over de regulatoren van deze apoptose. De apoptose
incidentie voor LVAD ondersteuning was laag (0.8% van de cardiomyocyten),
en nam nog verder af na LVAD ondersteuning (0.1% van de  cardiomyocyten).
Apoptose inducerende mediatoren en hun specifieke receptoren waren zowel
voor als na LVAD ondersteuning aanwezig. Het apoptose remmende eiwit FLIP
was in ruime mate aanwezig in de cardiomyocyten, zowel voor als na LVAD
ondersteuning, waarbij m-RNA niveaus vergelijkbaar waren met die van de
normale controle groep. Dit suggereert dat FLIP een belangrijke rol speelt in het
voorkomen van cardiomyocyt apoptose.
Hoofdstuk 6 vergelijkt de morfologie van de contractiele eiwitten in
biopten van de linker- en rechter ventrikel en het interventriculaire septum, om
te beoordelen of rechter ventrikel biopten gebruikt zouden kunnen worden
voor het aantonen van herstel in de linker ventrikel tijdens ondersteuning met
een LVAD. Rechter ventrikel biopten kunnen namelijk vrij makkelijk verkregen
worden via het aanprikken van de vena jugularis interna in de hals. Bij 13
patiënten met ernstig hartfalen werden myocard biopten, afgenomen na LVAD
ondersteuning, tijdens de harttransplantatie, vergeleken middels
immunohistochemie met antistoffen tegen de contractiele eiwitten. Het
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expressiepatroon van de contractiele eiwitten bleek identiek in de linker- en
rechter ventrikel biopten evenals in de biopten afgenomen uit de rechter kant
van het interventriculaire septum. Tevens werd gezien dat biopten, afgenomen
met behulp van een diagnostisch bioptoom representatief waren voor de
grotere biopten. Wat betreft de morfologie van de contractiele eiwitten kunnen
rechter ventrikel biopten dus gebruikt worden om herstel van linker ventrikel
functie aan te tonen tijdens LVAD ondersteuning.
Hoofdstuk 7 bevat een algemene discussie naar aanleiding van de
resultaten van dit proefschrift. Mechanische ondersteuning van de circulatie
heeft ondertussen al een belangrijke plaats verworven als overbrugging naar
harttransplantatie. Patiënten met ernstig hartfalen die dreigen te overlijden
kunnen op deze manier in leven worden gehouden, in afwachting van een
donor hart. Deze behandeling lost echter het tekort aan donororganen niet op.
Vermoedelijk zal echter binnen afzienbare tijd mechanische ondersteuning
gebruikt kunnen worden als alternatief voor harttransplantatie. Hiermee kan het
probleem van het tekort aan donor harten natuurlijk wel opgelost worden. Het
gebruik van mechanische ondersteuning  om de eigen hartfunctie langdurig te
laten herstellen, moet momenteel als uiterst experimenteel en onvoorspelbaar
worden beschouwd. Alleen potentieel herstelbare aandoeningen, zoals
bijvoorbeeld myocarditis, kunnen zoveel herstel tonen dat verwijdering van het
LVAD gerechtvaardigd is. Het idee om mechanische ondersteuning te
gebruiken als tijdelijk hulpmiddel om in de tussentijd te proberen met
uitgebreide aanvullende therapie langdurig herstel van de linker ventrikel
functie te bewerkstelligen, is op zich aantrekkelijk. Daarvoor is het nodig
uitgebreid onderzoek te doen naar dit herstelproces en de daarbij betrokken
regulatoren. Tevens dient bepaald te worden hoe dit proces van herstel het best
gemonitord kan worden en of dit ook leidt tot een blijvend herstel.
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Dankwoord
Aan het einde van dit proefschrift wil ik graag iedereen bedanken die heeft
bijgedragen aan de totstandkoming ervan. In het bijzonder wil ik noemen:
Mijn promotororen Prof. dr. E.O. Robles de Medina en Prof. dr. J.G. van den
Tweel. Etienne ben ik zeer veel dank verschuldigd, omdat hij me de
gelegenheid heeft geboden dit onderzoek te verrichten en mij altijd heeft
gestimuleerd. Hij was altijd geïnteresseerd in de vorderingen en bereid de
manuscripten van vele verbeteringen te voorzien. Het is tragisch dat hij, door
zijn ziekte en voortijdig overlijden, niet meer de afronding heeft kunnen
meemaken, maar ik weet zeker dat hij er trots op zou zijn geweest.
Beste Jan, hartelijk dank voor de mogelijkheid dit onderzoek grotendeels
binnen jouw afdeling te laten plaatsvinden. Het onderschrijft de al jarenlang
bestaande goede samenwerking tussen onze vakgroepen.
Mijn copromotoren  Dr. R.A. de Weger en Dr. F.H.J. Gmelig-Meyling.
Beste Roel, jouw steun bij dit proefschrift was onmisbaar. Zonder jouw hulp
zou dit proefschrift er nooit gekomen zijn. Het is, denk ik, een goede zet
geweest, om het al jarenlang lopende harttransplantatie onderzoek ook uit te
breiden in de richting van het hartfalen. Dit proefschrift moet gezien worden
als het eerste resultaat hiervan. Ik hoop dat er nog vele zullen volgen en
verheug mij op voortzetting van de goede samenwerking.
Beste Frits, binnen de samenwerking speelde jij een belangrijke rol als back-
bencher en wist op strategische momenten zinvolle ondersteuning te geven.
Ook je tekstuele aanvullingen heb ik erg op prijs gesteld.
De leden van de beoordelingscommissie, Prof. dr. P.J. Slootweg, Prof. dr.
A. Brutel de la Rivière, Prof. dr. C. van Echteld, Prof. dr. J. Klumperman en Prof.
dr. D.J. van Veldhuisen dank ik voor hun bereidwilligheid dit proefschrift
kritisch te beoordelen.
 Een bijzonder woord van dank gaat uit naar Dick van Wichen die bij dit
proefschrift een essentiële rol heeft gespeeld. Vol enthousiasme en met veel
vakkundigheid heeft hij al het bioptmateriaal bewerkt voor
immunohistochemie en heeft hij ook een belangrijke bijdrage geleverd bij de
beoordeling ervan. Hij was ook onmisbaar bij het maken van de fotopagina’s
en de uiteindelijke uitvoering van het boekje. Beste Dick, je bent de “stille
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kracht” waarop het hele lab Moleculaire en Immuun Pathologie leunt en voor
mij de grote steunpilaar waardoor het mogelijk was om naast mijn klinische
werkzaamheden dit onderzoek te doen.
Dr. J.R. Lahpor verdient natuurlijk ook mijn speciale dank. Beste Jaap, je
speelt al vele jaren een belangrijke rol in het Utrechtse harttransplantatie
programma. Zonder jou zou vermoedelijk de mechanische ondersteuning bij
terminaal hartfalen in Utrecht niet zover zijn gekomen, als die nu is. Je
flamboyante karakter draagt ruimschoots bij aan ons adagium: ”never a dull
moment”.
Mijn directe collega’s dr. J.H. Kirkels en drs. C. Klöpping. Beste Hans en
Corinne, ik denk dat we er trots op mogen zijn dat de “pioniers-afdeling” van
indertijd is uitgegroeid tot een volwaardige afdeling voor de behandeling van
patiënten met ernstig hartfalen, met diverse behandelingsmogelijkheden,
waaronder harttransplantatie en mechanische ondersteuning. Hier hebben
jullie een belangrijke rol in gespeeld. Ik wil jullie bedanken voor alle hulp die
jullie me hebben geboden bij het onderzoek en de extra tijd die ik heb kunnen
gebruiken voor de afronding van dit proefschrift.
Onze secretaresses, Bea Vlasblom en Hanneke Schuurs dank ik voor de
soepele manier waarop ze altijd de organisatie draaiende weten te houden en
structuur weten aan te brengen in de chaos die bij hen op het bureau wordt
gestort. Tevens een woord van dank aan onze verpleegkundige (NP) Albert
Oosterom, de regelneef van het team, die voor bijna alles wel een oplossing
heeft en overal kan bijspringen waar het nodig is. Albert, dit boekje toont waar
al die “vrije” dagen goed voor waren. Natuurlijk mag ik ook onze transplantatie
coördinator Patricia Batavier niet vergeten, al was het alleen maar voor de
koffie die ze ‘s morgens vroeg voor iedereen inschenkt. Maar ook haar
relativerende kijk op de wereld werkt vaak verhelderend.
De analisten van het “HTx-immunologie-pathologie” lab (waar zit dat
eigenlijk?), met name Annette, Joyce en Yevan, verrichten veel werk, waardoor
onderzoek als dit mogelijk is.  Zij zorgen onder andere voor de opvang,
bewerking en archivering van bloed en biopten van de patiënten en zijn nooit
te beroerd om een speurtocht door het ziekenhuis te houden op zoek naar
verdwenen materiaal. Ze zijn altijd zeer enthousiast en betrokken bij de
klinische zaken. In het begin leek het wel eens dat wij twee verschillende talen
spraken, maar geleidelijk aan zijn we elkaar steeds beter gaan begrijpen. Ook
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mijn “collega-promovendus” Femke dank ik voor haar bijdrage aan het
onderzoek en wens haar succes toe bij haar eigen promotie.
Mijn paranimfen, dr. Huub Meijburg en drs. Paul Westendorp, collega’s
uit de opleidingstijd in het “oude” ziekenhuis aan de Catharijnesingel (those
were the days) wil ik bedanken voor hun ondersteuning bij mijn promotie. Het
succes van onze combi zeven jaar geleden sterkt mij enigszins in de gedachte
dat het wel moet lukken.
Mijn collega’s van de maatschap Cardiologie van het Hart Long Centrum
Utrecht wil ik bedanken voor hun steun bij de totstandkoming van dit
proefschrift: dr. Carl Ascoop, drs. Egbert Bal, dr. Jurrien ten Berg, dr. Maarten-
Jan Cramer, drs. Richard Derksen, drs. Frank Eefting, dr. Sjef Ernst, prof. dr.
Richard Hauer, dr. Wybren Jaarsma, dr. Peter de Jaegere, dr. Hans Kirkels, drs.
Corinne Klöpping, dr. Peter Loh, drs. Gijs Mast, dr. Thijs Plokker, dr. Benno
Rensing, dr. Rienk Rienks,  dr. Maarten-Jan Suttorp, drs. pieter Stella en dr. Erik
Wever.
Tenslotte, Maria, Lisa, Simon en Ireen, mijn dierbaarsten. Eigenlijk mocht
ik niets over jullie schrijven in dit boekje, maar ik neem toch maar de vrijheid
om dat wel te doen. De afgelopen tijd is misschien wat hectisch geweest, maar
jullie zorgden in elk geval voor een stabiel thuisfront, met de nodige afleiding.
Jullie veel dank voor alle steun en begrip.
152
Curriculum Vitae
De auteur van dit proefschrift werd geboren op 6 augustus 1957 te Driebergen-
Rijsenburg. Hij behaalde in 1975 het diploma Atheneum-B aan het Revius
Lyceum te Doorn. In datzelfde jaar begon hij met de studie Geneeskunde aan
de Universiteit Utrecht. Tijdens de studie werkte hij als student-assistent bij de
vakgroep Medische Anatomie en Embryologie. Na het behalen van het
artsexamen op 25 juni 1982, volgde de militaire dienstplicht. Deze bracht hij
door in het Militair Hospitaal A. Mathijssen te Utrecht, als arts-assistent
Inwendige geneeskunde (dr. M van Zoeren) en als arts-assistent cardiologie (dr.
B.K. Bootsma). Van 1984 tot 1986 volgde hij de vooropleiding Inwendige
geneeskunde in het Sophia ziekenhuis te Zwolle (dr. T. Tjabbes). In 1986
werkte hij als arts-assistent cardiologie in hetzelfde ziekenhuis (dr. R.
Enthoven). Daarna volgde hij van 1986 tot 1989 de opleiding Cardiologie in
het Academisch Ziekenhuis Utrecht (Prof. dr. E.O. Robles de Medina). Sinds
oktober 1989 is hij werkzaam als staflid cardiologie in het Academisch
Ziekenhuis Utrecht, met als aandachtsgebied hartfalen en harttransplantatie.
